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ABSTRACT 
Cancer continues to be a global health burden, especially in the economically 
developing regions. The complex nature of this cancer contributes to a range of 
clinical challenges. Breast, lung and cervical cancer are known to have the highest 
incidence and mortality rates globally. Although many therapeutic options are 
available to treat cancer, the efficacy of most therapies is hindered due to normal 
tissue toxicity and tumour resistance. Novel treatment strategies are thus warranted 
to address clinical challenges and significantly improve patient outcomes. More than 
50% of cancer patients receive radiotherapy throughout their illness. DNA damage 
resulting in cell death, as a consequence of ionising radiation exposure, has assisted 
in clinical tumour management. However, inherent and acquired resistance as well 
as the manipulation of essential pathways, like cell metabolism, have aided cancer 
cells to evade the toxic effects of radiotherapy. Increasing the therapeutic window of 
this treatment modality may benefit a large number of patients. There is evidence to 
suggest that ionising radiation may activate cell survival signalling pathways. 
Targeting the components of these pathways may modify cell metabolism and 
significantly radiosensitise cancer cells. Therefore, combining targeted therapy and 
ionising radiation may be a viable therapeutic strategy. 
The objective of this study was to inhibit molecular targets of key pathways which 
regulate cell survival, and expose breast, lung, cervical cancer and normal cell lines 
to doses of radiation, so as to establish potential therapeutic targets that may be 
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amenable to combined modality therapy, and formulate a cocktail of inhibitors to 
evaluate its radiosensitising capability and effect on cellular metabolic activity.  
 In this study, clonogenic assays were performed to determine the relative sensitivity 
of 6 cell lines (cancer: MDA-MB-231 (breast), MCF-7 (breast), HeLa (cervix) and 
A549 (lung); apparently normal: L132 (lung) and MCF-12A (breast)) to ionising 
radiation and inhibitor therapy. Mathematic modelling was used to determine the 
mode of interaction between EGFR, PI3K/mTOR, and BcL-2 inhibitors, as well as, 
the modifying effects of inhibitors on the radiosensitivity and metabolic activity of the 
cell lines. 
This study found that potential therapeutic benefit might be obtained by treating 
MDA-MB-231, MCF-7, HeLa and A549 cells with X-rays. The MCF-7 cell line 
showed the highest potential of therapeutic benefit with a greater than 2-fold higher 
radiosensitivity, relative to the normal MCF-12A cells. The A549 cell line showed the 
lowest potential for therapeutic benefit, when compared with the L132 cell line. 
Inhibition of PI3K and mTOR with NVP-BEZ235 resulted in a significant therapeutic 
benefit for the lung and cervical cancer cell lines, minor therapeutic benefit in the 
MCF-7 cell line, and no benefit for the MDA-MB-231 cell line. Bcl-2 inhibition with 
ABT-263 had either no effect on the MDA-MB-231 and A549 cell lines or resulted in 
potential therapeutic benefits for MCF-7 and HeLa cell lines. Pre-treatment of breast 
(MDA-MB-231 and MCF-7) and lung (A549) cancer cell lines with a cocktail of an 
EGFR (AG-1478), PI3K/mTOR (NVP-BEZ235), or Bcl-2 (ABT-263) inhibitors had an 
enhancing effect on radiosensitivity and cellular metabolic activity. The same 
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treatment provided radioprotection, and reduced the metabolic activity of the cervical 
cancer cell line, HeLa.   
  
These findings suggest that concurrent inhibition of EGFR, PI3K, mTOR, and Bcl-2 
during radiotherapy might improve the treatment response of breast and lung cancer 
in patients. Future studies validating these findings for lower inhibitor concentrations 
might be more relevant in the clinical setting, as systemic toxicity is a major concern. 
A study exposing cells to fractionated radiotherapy, after inhibitor pre-treatment, may 
further reveal the therapeutic potential of the inhibitors used in this study. Evaluating 
the effect of inhibitor pre-treatment and radiofrequency field, which have been shown 
to exhibit radiomodulatory effects on cancer and normal cell lines, may provide 
insight into the development of a novel therapeutic strategy.    
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OPSOMMING 
 
Kanker is steeds 'n wêreldwye gesondheidslas, veral in die ekonomies 
ontwikkelende streke. Die ingewikkelde aard van kanker dra by tot 'n verskeidenheid 
kliniese uitdagings. Dit is bekend dat bors-, long- en servikale kanker wêreldwyd die 
hoogste voorkoms en sterftesyfers het. Alhoewel daar baie terapeutiese opsies 
beskikbaar is om kanker te behandel, word die doeltreffendheid van die meeste 
terapieë ingeboet weens normale weefseltoksisiteit en gewasweerstand. Nuwe 
behandelingsstrategieë sal dus in alle waarskynlikheid kliniese uitdagings aanspreek 
en pasiëntuitkomste beduidend verbeter. Meer as 50% van kankerpasiënte ontvang 
radioterapie regdeur hul siekte. DNA-skade as gevolg van blootstelling aan 
ioniserende bestraling, wat lei tot seldood, het gehelp met die beheer van kliniese 
gewasse. Inherente en verworwe weerstand en die manipulering van noodsaaklike 
paaie, soos selmetabolisme, het kankerselle egter gehelp om die giftige effekte van 
radioterapie te ontduik. Die vergroting van die terapeutiese venster van hierdie 
behandelingsmodaliteit kan moontlik 'n groot aantal pasiënte bevoordeel. Daar is 
bewyse wat daarop dui dat ioniserende bestraling selle se 
oorlewingseingewingpaaie kan aktiveer. Die teikening van die komponente van 
hierdie paaie kan selmetabolisme moontlik verander en kankerselle beduidend 
sensitiseer vir radioterapie. Daarom kan die kombinasie van geteikende terapie en 
ioniserende bestraling 'n haalbare terapeutiese strategie wees. 
 
Die doel van hierdie studie was om molekulêre teikens van sleutelpaaie wat 
seloorlewing reguleer, te inhibeer, en bors-, long-, servikale kanker en normale 
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sellyne bloot te stel aan dosisse bestraling, om moontlike terapeutiese teikens daar 
te stel wat geskik is vir gekombineerde modaliteitsterapie, en 'n mengsel van 
inhibeerders te formuleer om die radiosensitiserende-vermoë en effek daarvan op 
sellulêre metaboliese aktiwiteit te evalueer. 
 
In hierdie studie is klonogene ondersoeke uitgevoer om die relatiewe sensitiwiteit 
van 6 sellyne (kanker: MDA-MB-231 (bors), MCF-7 (bors), HeLa (serviks) en A549 
(long) te bepaal; blykbaar normaal: L132 (long) en MCF-12A (bors)) tot ioniserende 
bestraling en inhibitorterapie. Wiskundige modellering is gebruik om die 
interaksiemodus tussen EGFR, PI3K / mTOR en BcL-2-inhibitors te bepaal, sowel as 
die modifiserende effekte van inhibitors op die radiosensitiwiteit en metaboliese 
aktiwiteit van die sellyne. 
 
Hierdie studie het bevind dat potensiële terapeutiese voordele verkry kan word deur 
MDA-MB-231, MCF-7, HeLa en A549 selle met X-strale te behandel. Die MCF-7-
sellyn het die grootste potensiaal vir terapeutiese voordele getoon met 'n meer as 
twee keer hoër radiosensitiwiteit, relatief tot die normale MCF-12A-selle. Die A549-
sellyn het die laagste potensiaal vir terapeutiese voordele getoon in vergelyking met 
die L132-sellyn. Die inhibering van PI3K en mTOR met NVP-BEZ235 het 'n 
beduidende terapeutiese voordeel ingehou vir die long- en servikale kankersellyne, 
geringe terapeutiese voordele in die MCF-7-sellyn, en geen voordeel vir die MDA-
MB-231-sellyn nie. Bcl-2-inhibering met ABT-263 het óf geen effek op die MDA-MB-
231 en A549-sellyne gehad nie, óf dit het potensiële terapeutiese voordele vir MCF-
7- en HeLa-sellyne ingehou. Voorbehandeling van bors- (MDA-MB-231 en MCF-7) 
en long(A549)-kankerselle met 'n mengsel van 'n EGFR (AG-1478), PI3K/mTOR 
(NVP-BEZ235), of Bcl-2 (ABT-263) inhibeerders het 'n verhoogde uitwerking op 
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radiosensitiwiteit en sellulêre metaboliese aktiwiteit gehad. Dieselfde behandeling 
het radiobeskerming en verlaagde metaboliese aktiwiteit van die servikale 
kankersellyn, HeLa, gebied. 
 
Hierdie bevindings dui daarop dat gelyktydige inhibering van EGFR, PI3K, mTOR en 
Bcl-2 tydens radioterapie die behandelingsrespons van bors- en longkanker by 
pasiënte kan verbeter. Toekomstige studies wat hierdie bevindings vir laer 
inhibitorkonsentrasie bevestig, kan meer relevant in die kliniese omgewing wees, 
aangesien sistemiese toksisiteit 'n groot bron van kommer is. 'n Studie wat selle 
blootstel aan gefraksioneerde radioterapie, ná voorbehandeling van die inhibitor, kan 
moontlik die terapeutiese potensiaal van die inhibitors wat in hierdie studie gebruik 
is, openbaar. Evaluering van die effek van inhibitorvoorbehandeling en 
radiofrekwensieveld, wat getoon het dat dit radiomodulatoriese effekte op kanker en 
normale sellyne kan hê, kan insig bied in die ontwikkeling van 'n nuwe terapeutiese 
strategie. 
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Delineations 
This study used inhibitors of EGFR, PI3K, mTOR and Bcl-2 to radiosensitise human 
cell lines (MCF-7, MDA-MB-231, MCF-12A, HeLa, A549, and L132). The expression 
levels of the selected targets in each cell line were not determined prior to inhibition, 
as these have been reported in several studies (Subik et al., 2010; Lida et al., 2011; 
Sundarraj et al., 2014; Hamunyela et al., 2015; Zhang et al., 2015). 
 
The research variables determined in this study are intrinsic cellular radiosensitivity, 
the potential therapeutic effect of X-rays, cytotoxicity of specific inhibitors of EGFR, 
PI3K, mTOR and Bcl-2, the potential therapeutic effect of inhibitors, inhibitor 
interaction, radiomodulatory effects of inhibitors given either singly or in combination, 
and treatment effect on cellular metabolic activity. 
 
The clonogenic survival, of the cell lines used in this study, was determined after X-
ray irradiation to enable comparison of intrinsic cellular radiosensitivity and the 
potential therapeutic benefit of X-rays. Cytotoxicity of inhibitors was determined, 
using the colony assay to extract the equivalent concentration for 50% cell kill (EC50) 
for each cell line. From this cytoxicity data, the combination indices were determined, 
and used to decipher the models by which inhibitors interacted with each other when 
combined in a cocktail. The EC50-values had also been used to determine the 
potential therapeutic benefit of inhibitor treatment and guide subsequent 
radiomodulatory experiments in which radiation modifying factors which were derived 
to determine how a particular inhibitor or inhibitor cocktail impacted on cellular 
radiosensitivty. The effect of a particular inhibitor or inhibitor cocktail in combination 
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with X-ray irradiation had on cell metabolic activity had also been evaluated. The 
change in radiosensitivity due to inhibitor and X-ray treatment had been compared to 
the change in metabolic activity to determine if there may be a relation between 
these variables. 
 
Limitations: 
 This work only used six cell lines: two breast cancer cell lines (MDA-MB-231, 
MCF-7), one apparently normal breast cell line (MCF-12A), one cervical 
carcinoma cell line (HeLa), one lung cancer cell line (A549) and one 
apparently normal lung cell line (L-132). 
 In section 3.6, the peculiarities in survival curves would produce unreliable α/β 
ratios, as a result of inhibitor pre-treatment. The mean inactivation dose (?̅?) of 
each survival curve had been used to derive the modification in 
radiosensitivity. To maintain uniformity the a/β ratios had also not be used in 
the parameters to determine the intrinsic radiosensitivity in section 3.1.   
 The study investigated the effect of pre-treating 6 cell lines with an equivalent 
dose that would kill 50% of the cell population (EC50) in combination with X-
ray irradiation. Evaluating lower or higher concentrations of inhibitor may lead 
to varying modulatory results.  
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1.1. INTRODUCTION 
 
Cancer remains a growing health burden worldwide. In 2018, an estimated 9.6 
million cancer-related deaths and 18.1 million new cases had been predicted to 
occur (Bray et al., 2018). As the world’s population continues to age and adopt 
unhealthy lifestyles, the incidence of cancer and cancer-related deaths are predicted 
to continue to climb (Jemal et al., 2011; Bray et al., 2018). Even though economically 
developed countries are experiencing lower incidence and mortality rates, the 
economically developing world, such as sub-Saharan Africa, has seen an increase in 
the incidence of cancer and cancer-related deaths (Jemal et al., 2011; Bray et al., 
2018). Thus, cancer poses a significant health burden globally, especially in the 
developing regions. 
 
There are various types of cancers, each developing and sustaining itself through 
unique biological processes. These processes bolster the complex nature of this 
disease and contribute to therapeutic challenges, and clinical outcomes can 
therefore range from very poor to excellent (Higgins et al., 2011; Misra et al., 2012). 
Although there are many therapeutic options available to treat cancer, most of these 
therapies have shortcomings as a consequence of high normal tissue toxicity and 
tumour resistance. New innovative treatment strategies are thus warranted, to 
address these clinical challenges. 
 
Radiotherapy has been used for decades as the primary therapy for many types of 
cancers. More than 50% of all cancer patients receive radiotherapy throughout the 
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duration of their illness (Baskar et al., 2012). Exposing cancer cells to ionising 
radiation has proved effective in gaining control of tumour size as it invokes damage 
to cellular DNA and induces cell death (Pearce et al., 2001; Liang et al., 2003; 
Buchholz, 2009; Duru et al., 2012).  
 
Radioresistant tumours constitute a significant clinical obstacle as they limit the 
effectiveness of radiotherapy (Duru et al., 2012; Li et al., 2012). Despite its benefits, 
radiotherapy is also damaging to normal tissue and, thus, many patients suffer from 
short-term and long-term side effects (Buchholz, 2009). A large number of patients 
would therefore benefit from any improvement in the efficacy of radiation therapy 
(Begg et al., 2011). 
 
The discovery of biological markers essential for the regulation of cancer cell 
survival, has led to the development of target-based therapies that are highly 
specific, less invasive and less toxic than conventional treatment (Normanno et al., 
2009). Unfortunately, treatment resistance, especially when single agents are used, 
is also a challenge for the efficacy of this treatment modality.  
 
There is evidence to suggest that cellular exposure to ionising radiation may activate 
potential therapeutic components of the cell survival signalling pathways that may be 
implicated in resistance to targeted therapy (Contessa et al., 2002; Escriva et al., 
2008; Chandarlapaty et al., 2012). It is also suggested that inhibiting these 
components may significantly radiosensitise cancer cells (Reisterer et al., 2004; No 
et al., 2009).  
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Taking the abovementioned into account, it can thus be reasoned that a viable 
therapeutic strategy for cancer management would be to combine targeted therapies 
with radiotherapy. The objective of this study was to develop potential therapeutic 
strategies, using radiotherapy in combination with agents that target specific cell 
signalling pathways which regulate certain hallmarks of cancer. 
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1.2. PROBLEM STATEMENT 
 
Advancements in cancer treatment have led to improved patient response. However, 
optimal patient benefit remains mostly unattainable as various clinical challenges still 
exist (Misra et al., 2012). Inherent and acquired resistance to treatment, which 
increases the risk of tumour recurrence, are just two of these challenges (Higgins 
and Baselga, 2011; Hurvitz et al., 2013). The heterogeneous expression of target 
antigens is another clinical obstacle in targeted therapy, as this may result in the 
inability to effectively target malignant cells with toxic levels of a single agent. This 
phenomenon has been demonstrated for radiopharmaceuticals, chemotherapeutic 
drugs and radioimmunotherapeutics (Kvinnsland et al., 2001; Akudugu et al., 2011; 
Akudugu and Howell, 2012a). Treatment of most cancers with a single agent has, 
therefore, had limited success and novel treatment strategies are crucial in 
addressing these therapeutic challenges. 
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1.3. LITERATURE REVIEW 
 
1.3.1. Cancer 
 
Originating in the body, cancer is a somatic disease which is characterised by 
irregular cell proliferation and apoptosis (programmed cell death). Most cancers are 
thought to develop as a consequence of a series of DNA repair abnormalities which 
ultimately establishes a growth advantage for the clones of cancer cells in which 
these repair processes have occurred (Bamford et al., 2004). These cells possess 
the ability to be self-sufficient in growth signalling and insensitive to anti-growth 
signalling. Tumour cells generate their own growth signals so that they may be 
independent of growth stimulation from their normal tissue microenvironment. The 
dysregulation of growth signals and their respective receptors enable cancer cells to 
be hyper-responsive to growth stimuli that would normally not trigger their 
development. It allows these cells to remain independent from external growth 
factors. These characteristics assist in the ability of cancers to evade apoptosis and 
replicate continuously (Hanahan and Weinberg, 2000, 2011).  
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Figure 1.1: Hallmarks of cancer and the cellular responses invoked by exposing 
cancer cells to ionising radiation (Boss et al., 2014). 
 
Many cancers may also sustain themselves through the initiation and development 
of new blood vessels (angiogenesis), which provide nutrients and oxygen. These 
cells may alter their energy metabolism to a state favouring the development of new 
cancer cells. Cancer cells are able to spread (metastasise) from their original 
location to other parts of the body or infiltrate the surrounding tissue (Hanahan and 
Weinberg, 2000, 2011). Figure 1.1 elucidates the self-sustaining characteristics of 
cancer and the cellular responses to ionising radiation. An example of this 
phenomenon would be the lethal DNA damage and p53 gene activation, caused by 
exposing these cells to ionising radiation, which may lead to programmed cell death. 
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This response to ionising radiation may be in conflict with the resisting cell death, 
evading growth factors and replicative immortality hallmarks of cancer (Boss et al., 
2014).  
 
Generally, there are more than 200 different types of cancers with characteristics 
dependent on their tissue of origin (Madani et al., 2011). Lung, breast and cervical 
cancer have the highest incidence and mortality rates globally (Bray et al., 2018). 
Thus, further evaluation of new therapeutic approaches for these cancers is 
warranted. 
 
1.3.1.1. Breast Cancer 
 
Breast cancer is the most commonly diagnosed cancer and the leading cause of 
cancer-related death among women worldwide (Bray et al., 2018). It accounts for 
one in every four cancer cases among females (Bray et al., 2018). This 
heterogeneous disease originates from the mammary gland epithelium and is 
categorised into various subtypes, with unique molecular profiles, which impact 
histopathological presentation and clinical responses (Perou et al., 2000; Park et al., 
2012; Kondov et al., 2018). These subtypes are defined by the levels of expression 
of the oestrogen receptor (ER), progesterone receptor (PR), and the human 
epidermal growth factor receptor-2 (HER-2) on the membrane of the malignant cells, 
and the level of the Ki67 antigen expression (Kondov et al., 2018). There are five 
frequently used categories which sub-divide breast cancer, namely:  luminal A, 
luminal B, HER-2 enriched, basal-like (triple negative), and normal breast cell-like. 
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Luminal breast cancers are the most frequently diagnosed subtypes (Kondov, et al. 
2018). The luminal A subtype is commonly diagnosed in older patients. It is defined 
by positive ER and PR expression, a lower HER-2 expression, and a lower 
proliferative index (Ki67 < 14% expression). This subtype constitutes 50-60% of all 
breast cancers. Luminal A breast cancer is associated with good tumour 
differentiation, better treatment response and a lower risk of local recurrence or 
relapse. Thus, patients diagnosed with this subtype of malignant breast cancer have 
a better prognosis (van Diest et al., 2004; Carey et al., 2007; Vallejos et al., 2010; 
Yesral et al., 2014; Hashmi et al., 2018).        
 
Luminal B breast cancer is commonly diagnosed in younger patients and constitutes 
15-20% of all breast cancers. This subtype is characterised by positive ER and PR 
expression, a positive or negative HER-2 expression and a higher proliferative index 
(van Diest et al., 2004; Carey et al., 2007; Vallejos et al., 2010; Hashmi et al., 2018; 
Kondov et al., 2018).  When compared to the luminal A subtype, luminal B breast 
cancer is more aggressive and is associated with poor tumour differentiation and 
poor patient prognosis (van Diest et al., 2004; Carey et al., 2007; Vallejos et al., 
2010; Yesral et al., 2014; Hashmi et al., 2018).   
 
The HER-2 enriched subtype is an aggressive non-luminal malignancy defined by 
HER-2 overexpression, a high proliferative index, negative ER and PR expression 
and a p53 mutation (Bacus et al., 1990; Goldhirsch et al., 2011; Kondov et al., 2018). 
This subtype also correlates with poor tumour differentiation, a poor clinical outcome 
and a low patient survival rate (Bacus et al., 1990; Goldhirsch et al., 2011; Kondov et 
al., 2018). 
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Devoid of ER, PR and HER-2 expression, the basal-like breast cancer subtype is an 
extremely aggressive carcinoma with the highest proliferative index, the worst patient 
prognosis and clinical outcome, and a higher risk of recurrence (Cheang et al., 2008; 
Leidy et al., 2014; Masood et al., 2016; Kondov et al., 2018). 
 
The normal breast cell-like cancer subtype constitutes 5-10% of breast cancers. This 
subtype is poorly characterised and is said to be defined by its lack of ER, PR and 
HER-2 expression. The existence of this subtype has been questioned as some 
researchers believe that its discovery was due to a technical artefact from 
contamination with normal tissue during microarrays (Weigelt et al., 2010; Yersal and 
Baructa, 2014).  
 
1.3.1.2. Cervical Cancer 
 
Cervical cancer is ranked fourth of the cancers with the highest incidence and 
mortality rates globally, and is a rapidly growing burden in middle-low income 
countries, due to under-resourced health systems (Allemani et al., 2017; Ginsburg et 
al., 2017; Bray et al., 2018). Persistent infection by the human papillomavirus (HPV), 
immunosuppression and smoking are factors attributed to the development of 
cervical cancer (Allemani et al., 2017; Ginsburg et al., 2017). HPV oncogenic 
subtypes, HPV 16 and HPV 18, have been detected in most of the cervical cancer 
cases, and are thought to be the major contributing factors in its development 
(Colombo et al., 2012). There are three histological classifications of cervical cancer, 
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namely, squamous carcinoma, adenocarcinoma (glandular) and an undifferentiated 
carcinoma (Colombo et al., 2012).  
 
1.3.1.3. Lung Cancer  
 
The incidence of lung cancer is high and it is among the leading causes of cancer-
related mortalities worldwide (Bray et al., 2018). There are two major 
histopathological types of lung cancer, namely, non-small cell lung cancer (NSCLC) 
and small cell lung cancer (SCLC). NSCLC constitutes 85-90% of lung cancer cases, 
of which ~40% are adenocarcinomas, ~25-30% are squamous cell carcinomas and 
~10-15% are large cell carcinomas (Ginsberg et al., 2007; Novaes et al., 2008; 
Youlden et al., 2008; Lemjabbar-Alaoui et al., 2015). Lung cancer is a 
heterogeneous, highly invasive, extremely aggressive and rapidly metastasising 
carcinoma, and patients often present to the clinic at an advanced stage (Lemjabbar-
Alaoui et al., 2015). These factors largely have a negative impact on patient 
prognosis and treatment outcome. 
 
1.3.2. Cancer Therapy 
 
Surgery, chemotherapy and radiotherapy have been used as the mainstay of cancer 
therapy for decades. Although the response to the various treatment modalities has 
been high, many patients still relapse years later, creating various therapeutic 
challenges (Karrison et al., 1999; Weckermann et al., 2001; Pfitzenmaier, et al. 
2006; Aguirre-Ghiso, 2007). Radiotherapy is the focus of the investigation reported 
herein. 
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1.3.2.1. Radiotherapy 
 
A typical form of radiation is energy (or photon) that travels and is emitted as it 
moves through its travel path. It forms part of a spectrum called the electromagnetic 
spectrum which categorises different forms of radiation in terms of energy, 
wavelength, or frequency (Kumar and Dangi, 2016). Clinical grade radiation 
possesses the highest energy, a short wavelength and the highest frequency on the 
electromagnetic spectrum. It is said to be ionising, since it charges (or ionises) the 
molecules it transfers the energy to, and possesses biologically hazardous 
properties (Kumar and Dangi, 2016). Figure 1.1 is an illustration of how ionising 
radiation interacts with atoms or molecules. 
 
 
 
Figure 1.2:  Ionising radiation (γ-rays) interacting with an electron, has direct or indirect effects on 
DNA (Desouky et al., 2015). 
 
Ionising radiation, such as X-rays and gamma rays (γ-rays), deposits energy 
sparsely through its path, and is characterised as low linear energy transfer (LET) 
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radiation. However, high LET radiation, such as neutrons and α-particles, deposit 
energy in an abundant, more dense manner (Desouky et al., 2015). Radiation has a 
direct or indirect effect on its target. In Figure 1.1, ionising radiation ejects an 
electron and directly causes damage to the nucleotide chain (direct effect), or it 
causes radiolysis of a water molecule and the resultant reactive oxygen species 
causes a nucleotide chain break (indirect effect) (Desouky et al., 2015).   
 
Direct cell injury is predominantly caused by high LET radiation and includes 
deoxyribonucleic acid (DNA), ribonucleic acid (RNA), lipid, and protein damage. 
Indirect damage is mostly caused by low LET radiation which, through its interaction 
with water, generates reactive oxygen species, especially superoxide and hydroxide 
radicals, which have an effect on DNA, RNA, lipids, and proteins, as well as, the 
intracellular signalling pathways (Rhee 1999; Rhee et al., 2003; Bubici et al., 2006; 
Hall and Giaccia, 2006; Naumov and von Sonntag, 2008). 
 
DNA is the most critical target of radiation as it is vital to many cellular processes 
(Hutchison, 1966). Single- and double-strand breaks, along with nucleotide 
mutations occur during cellular exposure to ionising radiation. Double-strand breaks 
are the most lethal form of radiation damage, and may lead to mutagenesis or cell 
death, if not adequately repaired (Jonathan et al., 1999; Pollycove et al., 2003). 
Radiotherapy achieves therapeutic effect by inducing DNA damage and eventual cell 
death (Baskar et al., 2012). Evidence suggests that cancer cells produce more DNA 
breaks and repair damage at a slower rate than normal cells (Parshad et al., 1993; 
Shahidi et al., 2007; Mohseni-Meybodi et al., 2009; Shahidi et al., 2010). These 
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aspects, along with radiotherapy being non-invasive and cost-effective, make an 
attractive and effective treatment modality for cancer. 
  
Radiotherapy is a highly effective cancer management tool and is used for curative 
or palliative care (Prise, 2006; Guadagnolo et al., 2013; Liauw et al., 2013). Ionising 
radiation is clinically applied in multiple fractions and is used throughout the course 
of treatment for a large majority of cancer patients (Bentzen, 2006; Durante and 
Loeffler, 2010; Baskar et al., 2012; Moding et al., 2013). Patients who have had 
incomplete tumour resections or patients who have recurrent tumours are mostly 
treated with radiotherapy, while for patients with inoperable tumours, radiotherapy 
may be the only option (Durante and Loeffler, 2010).  
 
The response of tumours to radiation may be characterised according to the factors 
which influence the ability of ionising radiation to damage DNA, as well as, those that 
affect the DNA repair capacity of the tumour cell population (Brown and Brenner, 
2013). Repair of sublethal cellular damage, repopulation of cells after ionising 
radiation exposure, redistribution of cells within the cell cycle, reoxygenation of the 
surviving cells and intrinsic radiosensitivity, are the factors used to determine the net 
effect of ionising radiation on tumours (Brown et al., 2014). For fractionated doses of 
ionising radiation, redistribution and reoxygenation assist cell kill, as radioresistant 
cells are redistributed into more radiosensitive states over time and oxygen acts as a 
radiosensitiser. However, DNA repair and repopulation may elicit an increase in cell 
survival, as these factors allow for the recovery of cells, as well as, the proliferation 
of surviving cells after each fraction of radiotherapy (Brown et al., 2014).       
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Although radiotherapy is a mainstay treatment for cancer, radioresistance remains 
one of the major therapeutic obstacles hindering its effectiveness. Hypoxia is a 
common characteristic of tumours. In this tumour environment, devoid of oxygen, 
damaged DNA is not readily complexed with oxygen molecules (i.e. the damage is 
not “fixed” by oxygen). Unfixed damage is readily repaired and more cells survive, 
thus enhancing tumour radioresistance (Wang et al., 2019).  Cancer cells may also 
use a plethora of mechanisms to recover from the damaging effects of ionising 
radiation. Manipulating the tumour metabolism to provide sufficient energy and vital 
metabolites for DNA damage repair, regulating autophagy (self-eating) to protect 
damaged organelles, and cell cycle arrest to repair DNA damage, are a few 
examples of these phenomena (Tang et al., 2018). Radioresistance may lead to a 
poor prognosis, ultimately resulting in tumour recurrence and metastasis (Rycaj and 
Tang, 2014). 
  
Tumour control probability (TCP) and normal tissue complication probability (NTCP) 
are models used in the clinic to describe the relationship between the dose of 
ionising radiation and probability of tumour control or normal tissue complication 
(Chargari et al., 2015). The equilibrium between these models has been suggested 
to provide an indication of the therapeutic index of a treatment modality (Beasely et 
al., 2005). The development of treatment strategies which improve the therapeutic 
index of radiotherapy by increasing TCP and decreasing NTCP are thus required to 
enable clinicians to design effective treatment regimens. 
 
Exposure to ionising radiation activates the signal transduction pathways which 
confer treatment resistance through intrinsic or acquired biological processes 
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(Toulany and Rodemann, 2013). These signalling pathways may provide cancer 
cells with the means to evade cell death, through manipulating proliferation. An 
example is the survival pathway consisting of proteins such as the epidermal growth 
factor receptor (EGFR), phosphatidylinositol 3-kinase (PI3K) and the mammalian 
target of rapamycin (mTOR).  
 
1.3.2.2. Targeted Therapy 
 
The increasing understanding of the oncogenic process has driven the development 
of molecular target agents for cancer therapy. These drugs specifically target 
molecules that play critical roles in tumour growth, progression or cell survival.  
 
Targeted therapy has many other options, such as, signal transduction inhibitors, 
gene expression modulators, apoptosis inducers, angiogenesis inhibitors, and 
immunotherapies. Although there are many options available, most targeted 
therapies are hindered by the development of treatment resistant cancer cells (Burris 
et al., 2013). Resistance to targeted therapy may be acquired through the loss of 
target expression which may occur as a result of continuous exposure to therapy and 
the activation of additional pathways that promote cell survival (Higgins and Baselga, 
2011). The heterogenic distribution of target expression may contribute to target 
specific treatment resistance. The target antigen may be expressed at varying levels 
the single-cell level in a particular cell population. This may lead to the inability to 
effectively target all cells with a toxic level of a therapeutic agent. This phenomenon 
has been demonstrated for radiopharmaceuticals, chemotherapeutic drugs, and 
radioimmunotherapeutics (Kvinnsland et al., 2001; Akudugu et al., 2011; Akudugu 
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and Howell, 2012a, b). Variations in target morphology may also limit the 
effectiveness of targeted therapy. This has led to the search for more effective 
targets and treatment strategies. 
 
Trastuzumab and lapatinib are two examples of clinically available targeted therapies 
that have become standard treatment for HER-2 positive breast cancer. 
Trastuzumab is a monoclonal antibody which targets the extracellular domain of the 
HER-2 receptor, and lapatinib is a tyrosine kinase inhibitor that targets the 
intracellular domain of HER-2 and epidermal growth factor receptor (EGFR) (Hurvitz 
et al., 2013). A change in antigen shape may make it difficult for this antigen-specific 
agent to bind to the relevant target and exert its toxic effect, as seen in breast cancer 
cells expressing truncated HER-2 (p95HER-2). Truncated HER-2 lacks the epitope 
for trastuzumab, which is found in the full length version of this receptor (Zagozdzon 
et al., 2011). Figure 1.2 shows how EGFR is involved in numerous vital cellular 
processes.  
   
Stellenbosch University https://scholar.sun.ac.za
18 
 
 
 
Figure 1.3: EGFR signalling pathway. Ligand binding activates the EGFR dimer, which transduces its 
activating signal to downstream pathways, thus regulating vital cellular protocols (Huang and Fu, 
2015).    
 
The EGFR is a membrane bound tyrosine kinase receptor which plays a major role 
in regulating downstream proteins, PI3K and mTOR. These proteins ultimately 
regulate signal transducers and transcription activators, impacting genes associated 
with cell survival and proliferation (Rodemann and Blaese, 2007; Rodemann et al., 
2007).  These pathways are said to regulate most of the self-sustaining hallmarks of 
cancer (Huang et al., 2000; Nyati et al., 2006).  The PI3K-AKT-mTOR signalling 
pathway, a higher activated pathway in human tumours, is regarded as one the most 
challenging survival signalling pathways in cancer treatment resistance (Engelman, 
2009; Castellano et al., 2011).  Targeting these proteins with the appropriate 
inhibitors may be an effective strategy to manipulate cancer treatment resistance. 
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1.3.2.2.1. EGFR 
 
Also known as HER1/ErbB1, EGFR is part of a four-member transmembrane 
tyrosine kinase family which also includes HER2 (ErbB2/Neu), HER3 (ErbB3), HER4 
(ErbB4) (Higashiyama et al., 2008; Pines et al., 2010). The expression of EGFR in 
normal cells is estimated to be from 40 000-100 000 receptors per cell (Carpenter 
and Cohen, 1979). Activation of EGFR initiates signal transduction to a variety of 
downstream pathways which regulate cell proliferation, differentiation, survival, cell 
cycle progression, apoptosis inhibition, angiogenesis, invasion/metastasis, and other 
tumour promoting activities (Oda et al., 2005; Normanno et al., 2006; Black and 
Dinney, 2008; Uberall et al., 2008; Eccles, 2011; Mangelberger et al., 2012). 
 
The structure of this receptor consists of an extracellular ligand binding domain, a 
dimerisation arm, an intracellular domain associated with tyrosine kinase activity and 
a C-terminal tail, which are involved in signal transduction (Higashiyama et al., 2008; 
Roskoski, 2014). The formation of homogeneous or heterogeneous dimers with itself 
and other members of its family is vital for the activation of EGFR (Lemmon et al., 
2010). Ligand binding is crucial to EGFR activation and dimerisation. A number of 
ligands activate EGFR, namely, epidermal growth factor (EGF), transforming growth 
factor-α (TGF-α), amphiregulin (AREG), epiregulin (EREG), betacellulin (BTC), 
heparin-binding EGF-like growth factor (HB-EGF), and epigen (EPI) (Singh et al., 
2016). EGF, TGF-α, HB-EGF and BTC are suggested to have a high-affinity for 
EGFR, whereas AREG, EREG and EPGN are thought to have a lower affinity 
(Singh, et al. 2016).  
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Ligand affinity has been shown to be affected by pH. It has been reported that EGF 
and TGF-α may bind to EGFR with similar affinities at a relatively neutral pH of 7.4, 
whereas, a slightly acidic pH (pH 6) leads to the dissociation of TGF-α from EGFR 
(French et al., 1995).  
 
The ligands of juxtacrine, paracrine, and endocrine origins depend on the biological 
event that triggered their activation of EGFR. EGF production is typically locally 
controlled, as opposed to being delivered, as in the case of hormones, which allows 
different organs to elicit their own EGF-mediated response (Singh and Harris, 2005; 
Conte and Sigismund, 2016). Once EGF and related ligands have been released 
into the extracellular environment they begin to search for their cognate receptors, 
thereby, activating survival protocols (Massague and Pandiella, 1993; Sahin, et al. 
2004; Li et al., 2012; Chen et al., 2017). Even though these ligands may activate 
EGFR in a similar manner, individual ligands cause distinct downstream biological 
responses (Graus-Porta et al., 1997; Singh and Harris, 2005). 
 
EGFR ligand activation may occur through ligand binding, receptor dimerisation, 
receptor phosphorylation and the recruitment of signalling proteins or adaptors 
(Deurs, 2009). Ligand binding may also induce EGFR internalisation and transport to 
endosomes (Deurs, 2009). Active EGFR internalisation by endocytosis results in 
EGFR signal attenuation, and has been studied by many groups (Levkowitz et al., 
1999; Goh et al., 2010; Sousa et al., 2012; Wang et al., 2015; Conte and Sigismund, 
2016). 
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Generally, ligand activated EGFR leads to receptor dimerisation, 
transphosphorylation of the C-terminal tail and, finally, the propagation of the signal 
through signalling pathways to induce the expression of new genes. Ligand 
independent activation of EGFR occurs in EGFR mutations and truncated EGFR, 
which leads to the upregulation of oncogenesis.  
 
The role of EGFR in oncogenesis has made it an essential therapeutic target. Two 
major classes of EGFR-targeted therapies have been developed. The first class 
includes monoclonal antibodies which target the EGFR extracellular domain, 
designed to block ligand binding or to mediate the downregulation of the receptor 
(Martinelli et al., 2009). Cetuximab (Erbitux) and panitimumab (Vectibix) are 
examples of US FDA approved monoclonal antibodies. The second class includes 
tyrosine kinase inhibitors (TKIs). TKIs are ATP mimetics that bind to the receptor’s 
kinase pocket, which excludes ATP and prevents signal transduction (Paul and 
Mukhopadhyay, 2004). Approved TKIs include Erlotinib (Tarceva), Gerfitinib (Iressa), 
and Lapatinib (Tykerb).  
 
Anti-EGFR therapy has been shown to improve survival in EGFR-positive cancer 
patients (Harandi et al., 2009). However, therapeutic challenges limit the 
effectiveness of EGFR inhibitors. The response to anti-EGFR therapy can be 
modified by factors, such as, the type of somatic EGFR mutations, EGFR gene 
amplification, increased autocrine EGFR ligands, and mutations in EGFR signalling 
pathway proteins (Modjtahedi and Essapen, 2009; Bertotti et al., 2015). Another 
challenge facing the use of EGFR inhibitors is that the duration of the response is 
often limited, and many tumours invariably develop resistance (Bertotti et al., 2015). 
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1.3.2.2.2. PI3K 
 
The stimulation of EGFR through EGF binding leads to PI3K activation (Bjorge et al., 
1990). The PI3K family is classified into three sub-groups. Each group is separated, 
characterised by its structure, regulation and function (Thorpe et al., 2015). Class I of 
PI3K is a downstream effector of EGFR, and is further sub-classified into IA (PI3Kα, 
β, δ), which is activated by receptor tyrosine kinases, and IB (PI3Kγ) which is 
triggered by G-protein-coupled receptors (Fruman and Cantley, 2002). Furthermore, 
PI3K consists of a regulatory subunit p85 that mediates binding to the receptor and a 
catalytic p110 domain, which phosphorylates the 3-OH group of the membrane lipid 
phosphatidylinositol-4,5-biphosphate (PIP2), when PI3K is transported to the cell 
membrane, to generate phosphatidylinositol-3,4,5-triphosphate (PIP3) (Whitman et 
al., 1988; Auger et al., 1989; Carpenter, et al. 1990; Zhao and Vogt, 2008). PIP3 
recruits phosphoinositide-dependent kinase 1 (PDK1) and serine/threonine kinase 
Akt at threonine 308 (Cantley, 2002; Alessi et al., 1997). Phosphorylated Akt 
propagates this signal by activating Ras homolog enriched in brain (RHEB), which 
enables the activation of mammalian target of rapamycin (mTOR) (Manning and 
Cantley, 2003). 
 
In cancer, the PI3K signalling pathway located upstream of the mTOR complexes 
often consists of various mutations, such as the mutation and amplification of Akt 
and PIK3CA, and amplification of EGFR and insulin growth factor receptor (IGFR) 
(Guertin and Sabatini, 2007; Guertin et al., 2009; Liu et al., 2009). PI3K and Ras are 
parallel pathways, and amplification of growth factor receptors that are upstream of 
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either signal can also result in abnormal signal transduction on both mTOR 
complexes (Mayer and Arteaga, 2016). 
 
1.3.2.2.3. mTOR  
 
Mammalian/mechanistic target of rapamycin (mTOR) is a serine/threonine kinase 
which carries out its function through mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) which detect and consolidate cellular and environmental 
signals (Laplante and Sabatini, 2012; Saxton and Sabatini, 2017). These complexes 
regulate various stimuli, such as, nutrients, growth factors, energy, hormones and 
hypoxia. These complexes may also affect glucose metabolism through various 
mechanisms (Wullschleger et al., 2006; Laplante and Sabatini, 2012; Paquette et al., 
2018). 
 
The PI3K/Akt pathway plays a predominant role in the activation of mTORC1 (Zhang 
et al., 2007). mTORC1 phosphorylates downstream effectors, such as, eukaryotic 
translation initiation factor 4E binding protein 1 (4EBP1), S6 kinase (S6K), and sterol 
regulatory element-binding protein (SREBP), to encourage protein translation, 
synthesis of nucleotides and lipids, the recruitment of lysosomes and the 
suppression of autophagy (Ben-Sahra and Manning, 2017). mTORC1 may respond 
to fluctuations in cellular factors, such as, DNA damage, intracellular adenosine 
triphosphate (ATP), glucose, amino acids and oxygen. The p53 target genes are 
used by several pathways to suppress mTORC1 in response to DNA damage (Feng 
et al., 2005). They also promote the synthesis of proteins, lipids and nucleotides in 
aberrant cells, and tissue and organism growth in cancer (Azpiazu et al., 1996; 
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Peterson et al., 1999; Yokogami et al., 2000; Hudson et al., 2002; Huffman et al., 
2002; Saxton and Sabatini, 2017). mTOR activation also leads to an increase in cell 
size and proliferation (Fingar et al., 2002; Dowling et al., 2010). mTORC2 is localised 
at the plasma membrane where it binds to the substrates, Akt, serum glucose kinase 
(SGK), and protein kinase C (PKC), through the mammalian orthologue of Sin1 
(mSIN1) (Liu et al., 2015). This mTOR complex increases the rebuilding of the 
cytoskeleton and cell migration, inhibits apoptosis, and affects cell metabolism 
(Nobes and Hall, 1999). It also regulates cytoskeleton reorganisation and cell 
movement involved in tumour development (Jacinto et al., 2004; Sarbassov et al., 
2004; Gan et al., 2012; Thomanetz et al., 2013). 
 
mTOR signalling is enhanced in various types of cancers. This enhanced signal 
occurs in almost 30% of cancers and is one of the most frequently affected signalling 
pathways in cancer (Fruman and Rommel, 2014). Thirty-three mTOR mutations 
have been reported to contribute to the hyperactivation of mTOR signalling in cancer 
(Grabiner et al., 2014). mTOR activation in cancer depends on three mechanisms: 
mutations in the mTOR gene lead to a hyper-activated mTOR signalling pathway; 
mutations in mTORC1 and mTORC2 result in mTOR activation; an aberrant mTOR 
pathway may also be a consequence of mutations in upstream genes, loss-of-
function mutations in tumour suppressor genes and gain-of-function mutations in 
oncogenes (Conciatori et al., 2018). This activation regulates the cell proliferation 
and metabolism involved in tumour initiation and progression. Its activation also 
leads to increased ribosome synthesis, which provides the equipment to maintain 
enhanced cell growth (Laplante and Sabatini, 2012). 
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In cancer, the metabolism is manipulated to maintain the demands of rapid cell 
growth. The mTOR complex has been depicted as a nutrient sensor in the 
metabolism of cancer, especially of glucose and amino acids, nucleotides, fatty 
acids, growth factors and other stresses. Nutrient sensing activates mTORC1 and 
the metabolic changes in cancer cells and, in turn, sustains mTORC1 activation 
(Saxton and Sabatini, 2017; Harachi et al., 2018; Paquette et al., 2018; Mossmann 
et al., 2018). 
 
Glucose metabolism is used to provide energy for vital survival processes. mTORC1 
can enhance the translation of two key transcription factors, namely, hypoxia 
inducible factor (HIF)-1α and Myc, which drive expression of a variety of glycolytic 
enzymes to regulate glycolysis (Majumder et al., 2004; Gordan et al., 2007; Duvel et 
al., 2010). Glucose metabolism may also be affected by mTORC2, through the 
activation of Akt (Elstrom et al., 2004). mTORC1 activates the critical transcription 
factor sterol regulatory element-binding protein 1 (SRE-BP1), driving gene 
transcription in lipid synthesis via Akt activation and phosphorylation of Lipin1 and 
S6K1 (Porstmann et al., 2008; Peterson et al., 2011). Synthesis of purine and 
pyrimidine, significant for cancer DNA replication, can be promoted by mTORC1, via 
S6K1 phosphorylation (Ben-Sahra et al., 2013, 2016).  
 
mTOR is also involved in the regulation of autophagy, a process that degrades and 
recycles cytosolic components in response to a shortage of nutrients and energy. 
Autophagy is an inhibition process against tumorigenesis, and blockage of 
autophagy contributes to cancer initiation (White, 2015). mTOR involvement in these 
crucial cellular processes makes it a prime therapeutic target. 
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A study by Hamunyela and colleagues investigated whether treating low HER-2 
expressing human breast cancer cells with a cocktail of specific inhibitors of HER-2, 
PI3K and mTOR, namely, TAK-165 and NVP-BEZ235, would sensitise these cells to 
ionising radiation, and demonstrated a 2-fold radiosensitisation (Hamunyela et al., 
2015). In another study by Maleka and colleagues, the effect of pre-treating human 
prostate carcinoma and normal prostate cells with a cocktail of inhibitors targeting 
EGFR (AG-1478), and PI3K and mTOR (NVP-BEZ235) was investigated. It was 
found that while prostate cancer cells were radiosensitised, their normal counterparts 
were protected against the lethal effects of radiation when only PI3K and mTOR 
were inhibited with NVP-BEZ235 (Maleka et al., 2015). This could contribute to the 
development of a promising treatment strategy for prostate cancer, as NVP-BEZ235 
pre-treatment radiosensitised prostate cancer cells and protected normal prostate 
cells against ionising radiation exposure.   
 
1.3.2.2.4. BCL-2 
 
Apoptosis is a form of programmed cell death initiated by various physiological and 
pathological stimuli. Apoptosis is morphologically characterised by cell shrinkage 
followed by the formation of cell fragments cleared by phagocytosis (Hengartner, 
2000; Meng et al., 2006; Taylor et al., 2008). This cell death process involves the 
conversion of various signals into caspase-mediated intracellular protease activity 
(Earnshaw et al., 1999; Hengartner, 2000; Meng, et al., 2006). Figure 1.4 describes 
the intrinsic and extrinsic apoptotic pathways (Indran et al., 2011).  
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Figure 1.4: Description of intrinsic and extrinsic apoptotic pathways (Indran et al., 2011). 
 
The leakage of cytochrome C into the cytoplasm is synonymous with the activation 
of the mitochondrial apoptotic pathway (Liu, et al. 1996; van Delft and Huang, 2006; 
Wang and Youle, 2009).  This facilitates the recruitment of caspase 9 which 
activates the caspase cascade (Hengartner, 2000; Jiang and Wang, 2004; Taylor, et 
al. 2008).  
Cytochrome C release from the mitochondria into the cytoplasm is regulated by the 
Bcl-2 protein family. This family consists of: (i) pro-apoptotic proteins, Bcl-2-like 
protein 4 (Bax) and Bcl-2 antagonist killer 1 (Bak), which regulate the 
permeabilisation of the mitochondrial outer membrane; (ii) anti-apoptotic family 
members, Bcl-2, B-cell lymphoma-extra large (Bcl-XL), myeloid cell leukaemia-1 
(Mcl-1), B-cell leukaemia/lymphoma-w (Bcl-w) and Bcl-2 A1, which mediate the 
impermeabilisation of the mitochondrial outer membrane; and (iii) pro-apoptotic B-
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cell homology 3 (BH3)-only proteins, which promote apoptosis by binding to and 
oligomerising Bax and Bak or indirectly by neutralising anti-apoptotic family members 
(Strasser et al., 2011; Czabotar et al., 2014; Moldoveanu et al., 2014; Renault and 
Chipuk, 2014). 
 
The overexpression of anti-apoptotic proteins, Bcl-2 and Bcl-XL, has been reported 
to occur in a variety of tumours (Krajewski et al., 1997; Olopade et al., 1997; 
Scheinder et al., 1997; Pena et al., 1999; Trask et al., 2002).  Resistance to 
radiotherapy and chemotherapy and poor treatment response have also been 
associated with enhanced levels of Bcl-2 and Bcl-XL (Minn et al., 1995; Reed et al., 
1996; Simonian et al., 1997; Gallo et al., 1999; Ong et al., 2001).  
 
The survival proteins mentioned above play an essential role in cancer cell 
propagation and response to radiotherapy. Targeting these proteins with specific 
targeted therapy may assist in manipulating cancer cell radiosensitivity, and using 
these treatment modalities in combination may improve treatment outcomes. 
  
 1.3.2.3. Combination Therapy 
 
In combination therapy, one molecule may improve the action of another by 
increasing its penetration or preventing its destruction (Reece et al., 2007). A two-
fold rationale has been suggested for the use of concomitant therapy. Firstly, when 
multiple drugs with different targets are applied, the process of cancer cells adapting 
to therapy can be delayed. Secondly, multiple drugs targeting the same cellular 
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pathway could function synergistically for higher therapeutic efficacy and higher 
target selectivity (Lee and Nan, 2012). 
 
The combination of inhibitors and radiotherapy may compensate for the activation of 
survival signals after ionising radiation exposure elucidated in Section 1.3.2.1. 
Therefore, this study aimed to investigate whether a cocktail of targeted therapies 
can be used to target proteins pertinent to cancer hallmarks, to increase the 
radiosensitivity of cancer cells so that radiotherapy may be used to eliminate these 
cells.    
 
1.3.3. Cell Metabolism 
 
Cell metabolism is a term used to summarise the network of biochemical processes 
used by the cell to fulfil its various biological functions (DeBerardinis and Thompson, 
2012; Metallo and Vander Heiden, 2013; Fernandez-de-Cossio-Diaz and Vazquez, 
2018). Metabolism may be categorised into anabolic and catabolic processes 
(Metallo and Vander Heiden, 2013). Anabolic metabolism constitutes the building of 
macromolecules such as lipids and proteins. Catabolic metabolism constitutes the 
breaking down of molecules, such as the carbohydrate and glucose, to produce 
energy (Gomes and Blenis, 2015).  
 
An important hallmark of cancer cells, is the reprogramming of these processes to 
adapt to changes in their microenvironment and support their high metabolic activity 
requirements (Wellen and Thompson, 2010; Hanahan and Weinberg, 2011; 
Anastasiou, 2017; Muir et al., 2017).  
Stellenbosch University https://scholar.sun.ac.za
30 
 
 
Cell metabolism has also been suggested to play a role in DNA damage through the 
production of reactive oxygen species (Turgeon et al., 2018). This process has also 
been implicated in assisting DNA repair, as it produces metabolites which play an 
essential role in DNA structure and stability (Turgeon et al., 2018).  
 
The aberration of the survival PI3K-Akt-mTOR pathway has been suggested to 
assist cancer cells in manipulating metabolic activity to support the dysregulated 
development of these cells, previously elucidated in Section 1.3.2.2.3. 
Thus, monitoring the metabolic activity after treatment could provide insights into the 
cellular metabolic response to treatment and the cells’ ability to repair damage. 
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 1.4. HYPOTHESIS AND OBJECTIVES  
 
It is clear that improving the efficacy of radiotherapy and minimising its related 
normal tissue toxicity would be beneficial for a large percentage of cancer patients. 
Identification and manipulation of components of pathways which regulate the self-
sustaining hallmarks of cancer cells could overcome treatment resistance. The 
studies reported here sought to formulate combined treatment modalities that would 
target more than one of these components to effectively inhibit them and enhance 
the radiosensitivity of a selection of cancer cell lines. It is, therefore, hypothesised 
that inhibiting the activity of EGFR, PI3K, mTOR, and Bcl-2 can significantly sensitise 
cancer cells to ionising radiation and that this sensitising effect could correlate with a 
change in metabolic activity.  
 
To test this hypothesis, the specific study objectives are as follows: 
 
1. To determine the intrinsic radiosensitivity of a panel of breast, lung, and 
cervical cancer cell lines. 
2. To evaluate the effect of an EGFR, mTOR, PI3K, and BcL-2 inhibitors on the 
survival of the panel of cell lines in Objective 1. 
3. To evaluate potential interaction between inhibitors in the panel of cell lines in 
Objective 1.  
4. To investigate the effects of a combination of inhibitors and X-rays on the 
panel of cell lines in Objective 1. 
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5. To determine the effect of inhibitors and X-ray therapy on metabolic activity of 
the panel of cell lines in Objective 1.   
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CHAPTER 2 
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2. MATERIALS AND METHODS 
 
 
2.1. Study Location and Ethical Consideration 
 
All experiments were performed in the Division of Radiobiology, Faculty of Medicine 
and Health Sciences, Stellenbosch University, Tygerberg. The study was approved 
by the Health Research Ethics Committee (HREC) of the Faculty of Medicine and 
Health Sciences, Stellenbosch University, South Africa (HREC Reference #: 
X19/02/003; Appendix A). 
 
2.2. Cell Lines 
 
2.2.1. MCF-7 
 
MCF-7 is a human mammary adenocarcinoma-derived cell line established from a 
metastatic lesion. MCF-7 is classified as a luminal A breast cancer subtype (Subik et 
al., 2010). It has an epithelial-like morphology, is adherent and grows as a 
monolayer in Roswell Park Memorial Institute medium (RPMI-1640) (Sigma-Aldrich, 
USA, cat # R8758), supplemented with 10% heat-inactivated foetal bovine serum 
(FBS) (HyClone, UK, cat # SV30160.03), penicillin (100 U/ml) and streptomycin (100 
µg/ml) (Lonza, Belgium, cat # DE17-602E). A frozen vial of cells was obtained from 
Professor S. Prince (University of Cape Town, South Africa). MCF-7 was used 
between passages 7-17 for all experiments.  
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2.2.2. MDA-MB-231 
 
MDA-MB-231 is a human mammary adenocarcinoma-derived cell line established 
from a metastatic lesion. MDA-MB-231 is classified as a basal-like breast cancer 
subtype (Subik et al., 2010). It has an epithelial-like morphology, is adherent and 
grows as a monolayer in RPMI-1640 medium (Sigma-Aldrich, USA, cat # R8758), 
supplemented with 10% heat-inactivated foetal bovine serum (HyClone, UK, cat # 
SV30160.03), penicillin (100 U/ml) and streptomycin (100 µg/ml) (Lonza, Belgium cat 
# DE17-602E). The cells were obtained from Professor S. Prince (University of Cape 
Town, South Africa). MDA-MB-231 was used between passages 59-69 for all 
experiments. 
 
2.2.3. MCF-12A 
 
MCF-12A is a non-tumour-forming breast cell line derived from the excised breast 
tissue of a postmenopausal nulliparous female who had been diagnosed with a 
fibrocystic breast disease and had undergone a reduction mammoplasty (Sweeney 
et al., 2018; Paine et al., 1992), and was used to represent normal tissue for breast 
and cervical cancer. It has an epithelial-like morphology, is adherent and grows as a 
monolayer in Dulbecco’s modified Eagle’s medium / Nutrient Formulation F-12 HAM 
(Lonza, Belgium, cat # BE12-719F). This pre-constituted liquid growth medium was 
supplemented with 15 mM HEPES, 0.365 g/L L-glutamine, 1.2 g/L sodium 
bicarbonate, 20 ng/ml human epidermal growth factor (Sigma-Aldrich, Germany), 
0.01 mg/ml bovine insulin (Sigma-Aldrich, Germany), 500 ng/ml hydrocortisone 
(Sigma-Aldrich, Germany), 10% heat-inactivated foetal bovine serum (HyClone, UK, 
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cat # SV30160.03), penicillin (100 U/ml) and streptomycin (100 µg/ml) (Lonza, 
Belgium, cat # DE17-602E). The cells were obtained from Professor AM Engelbrecht 
(Stellenbosch University, South Africa). MCF-12A was used between passages 30-
40 for all experiments. 
 
2.2.4. HeLa 
 
HeLa is a cervical cancer cell line derived from an adenocarcinoma of the cervix 
(Korch and Varella-Garcia, 2018; Lucey et al., 2009). It has an epithelial-like 
morphology, is adherent and grows as a monolayer in McCoy’s 5A medium (Sigma-
Aldrich, USA, cat # M9309), supplemented with 10% heat-inactivated foetal bovine 
serum (HyClone, UK, cat # SV30160.03), penicillin (100 U/ml) and streptomycin (100 
µg/ml) (Lonza, Belgium cat # DE17-602E). The cells were a gift from Professor E. 
van Helden (Stellenbosch University, South Africa). HeLa was used between 
passages 8-18 for all experiments. 
  
2.2.5. A549 
 
A549 is a human adenocarcinoma cell line derived from human lung cancer tissue 
(Yamagata et al., 2018). It has an epithelial-like morphology, is adherent and grows 
as a monolayer in RPMI-1640 medium (Sigma-Aldrich, USA, cat # R8758), 
supplemented with 10% heat-inactivated foetal bovine serum (HyClone, UK, cat # 
SV30160.03), penicillin (100 U/ml) and streptomycin (100 µg/ml) (Lonza, Belgium cat 
# DE17-602E). The cells were purchased from Cellonex (Johannesburg, South 
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Africa, cat # CA54-C). A549 was used between passages 101-110 for all 
experiments. 
 
2.2.6. L132 
 
L132 is a human pulmonary epithelial cell line (Jin et al., 2019), and was used to 
mimic normal tissue for lung cancer. It has an epithelial-like morphology, is adherent 
and grows as a monolayer in RPMI-1640 medium (Sigma-Aldrich, USA, cat # 
R8758), supplemented with 10% heat-inactivated foetal bovine serum (HyClone, UK, 
cat # SV30160.03), penicillin (100 U/ml) and streptomycin (100 µg/ml) (Lonza, 
Belgium cat # DE17-602E). These cells were retrieved from the liquid nitrogen 
storage of the Division of Radiobiology (Department of Medical Imaging and Clinical 
Oncology, Stellenbosch University). L132 was used between passages 22-32 for all 
experiments. 
 
2.3. Cell Culture Maintenance    
 
All cell cultures were kept at 37ºC in a humidified atmosphere of 95% air and 5% 
CO2 in SHEL LAB incubators (Sheldon Manufacturing Inc., USA), and procedures were 
carried out in vertical laminar flow cabinets using aseptic techniques. Cells were 
routinely grown in 75 cm2 flasks and passaged at a cell culture confluency of 80 to 
90%. For cryopreservation, cells were trypsinised, pelleted by centrifugation (4000 
RPM for 5 minutes), resuspended in a mixture of 0.9 ml foetal bovine serum and 0.1 
ml of dimethyl sulfoxide (DMSO) (Sigma-Aldrich, USA, cat # 41640) stored at -80°C 
overnight, and then transferred to liquid nitrogen for use at a later stage. 
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2.4. Irradiation of Cell Cultures 
 
Cell culture irradiation was performed using a Precision MultiRad 160 X-irradiator 
(Precision X-Ray Inc., Branford, CT, USA) at the Division of Radiobiology (Faculty of 
Medicine and Health Sciences, Stellenbosch University). Samples were irradiated at 
a source-to-sample distance of 65 cm, measured to the base of the experimental 
flasks, at a dose rate of 1.0 Gy/min. For this, build-up also consisted of 5-10 ml of 
medium in the 25 cm2 culture flasks. In all cases, cell cultures were irradiated at 
room temperature (22ºC). 
 
2.5. Clonogenic Cell Survival Assay 
 
To determine the relative radiosensitivities of the breast cancer cell lines used in this 
study, clonogenic cell survival assays were performed. Near-confluent stock cultures 
were washed with sterile phosphate buffered saline (PBS) (Lonza, Belgium, cat # 17-
512F) trypsinised, and the cells counted using a haemocytometer. Cells were then 
seeded in triplicate per experiment in 25 cm2 tissue culture flasks at numbers 
ranging from 200 - 10 000 per flask, depending on radiation absorbed dose, and left 
to settle for 3-5 hours before being exposed to ionising radiation. Cells were 
irradiated to graded doses ranging from 0-10 Gy. After an appropriate incubation 
period (usually 7-14 days), the colonies were fixed by decanting the medium in the 
flask, and replacing it with 10 ml of fixative, and a mixture of glacial acetic acid, 
methanol and water in a ratio 10:10:8 v:v:v, for 10 minutes.  The fixative was then 
decanted and replaced with 10 ml of Amido Black stain, consisting of 10 ml of 0.01% 
Amido Black in 1 litre of fixative. The colonies were left to stain for 10 minutes. The 
Stellenbosch University https://scholar.sun.ac.za
39 
 
stain was then decanted, and the flasks left to dry. The colonies were counted using 
a dissection microscope. The means (± SD) of the surviving fractions (SF) for three 
experiments were plotted against the irradiation dose, and cell survival curves 
obtained by fitting the data to the linear-quadratic survival equation: 
 
SF= exp[-αD-βD2]                                  (2.1), 
 
where α and  are the linear and quadratic cell inactivation constants, respectively, 
and D is the dose in Gy (Cornforth and Loucas, 2019; Fertil et al., 1984). 
Radiosensitivity of cell lines was expressed in terms of the surviving fraction at 2 Gy 
(SF2), the surviving fraction at 6 Gy (SF6), absorbed dose for 50% cell killing (D50), 
and the mean inactivation dose (?̅?). ?̅? is the area under the cell survival curve and 
depicts radiosensitivity over low-high doses.  
 
2.6. Target Inhibitors  
 
Three inhibitors, AG-1478, NVP-BEZ235 and ABT-263, which targeted vital cell 
survival proteins, namely EGFR, PI3K, mTOR and Bcl-2, were used in this study. 
 
2.6.1. AG-1478 
 
AG-1478 is an epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 
of 3 nM in non-small cell lung cancer cells (Shi et al., 2018; Puri and Salgia, 2008; 
Levitzki and Gazit, 1995). AG-1478 has a molecular weight of 352.22 and a chemical 
Stellenbosch University https://scholar.sun.ac.za
40 
 
formula of C16H14ClN3O2HCl (Tocris Bioscience, UK, cat # 1276) and depicted 
structurally in Figure 2.1. 
 
For this study, a stock solution of 9.5 mM of AG-1478 was reconstituted in dimethyl 
sulfoxide (DMSO) and stored at -20ºC until needed. 
 
 
Figure 2.1: Chemical structure of AG-1478. 
 
2.6.2. NVP-BEZ235 
 
NVP-BEZ235 is a dual phosphoinositide-3-kinase (PI3K) and mammalian target of 
rapamycin (mTOR) inhibitor with an inhibitory concentration for 50% inhibition of 
p110 activity and an IC50 of 7 nM (Maira et al., 2008). Biochemically, NVP-BEZ235 
reversibly inhibits class 1 PI3K catalytic activity by competing for its ATP-binding 
sites. It also inhibits mTOR catalytic activity but does not target other protein kinases 
(Maira et al., 2008). NVP-BEZ235 has a molecular weight of 469.55 and chemical 
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formula C30H23N5O (Santa Cruz Biotechnology, Texas, USA, cat # 364429), and is 
soluble in DMSO. Figure 2.2 is an illustration of the chemical structure of NVP-
BEZ235. 
 
For this study, a stock solution of 106 mM NVP-BEZ235 was reconstituted in 
dimethyl sulfoxide and stored at -20ºC until needed. 
 
 
Figure 2.2: Chemical structure of NVP-BEZ235. 
 
2.6.3. ABT-263 
 
ABT-263 (C47H55ClF3N5O6S3; MW = 974.61; a gift from the Chemotherapeutic 
Agents Repository of the Drug Synthesis and Chemistry Branch, National Cancer 
Institute, USA)(Abcam, UK, cat # ab218114), depicted structurally in figure 2.3, is a 
Bad-like BH3 mimic for Bcl-2, Bcl-xl, and Bcl-w, with an IC50 of < 1nM (Tse et al., 
2008). ABT-263 disrupts Bcl-2/Bcl-xL interactions with pro-death proteins, leading to 
induced apoptosis within 2 hours after treatment. More so, in human cancer cells, 
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ABT-263 induces Bax translocation, Cytochrome C release, and subsequent 
apoptosis (Bajwa et al., 2012).  
 
For this study, the stock solution consisted of 0.955 mM of ABT-263, in DMSO, and 
was stored at -20ºC until needed. 
 
 
Figure 2.3: Chemical structure of ABT-263. 
 
 
2.7. Target Inhibitor Toxicity Measurements 
 
Single-cell suspensions were seeded (200-4000 cells per flask) into 25 cm2 tissue 
culture flasks and incubated for 3-4 hours to allow the cells to attach. To assess the 
influence of inhibitor concentration on cytotoxicity, cells were exposed to AG-1478 
(0.06-50 µM), NVP-BEZ235 (0.6-34 nM) and ABT-263 (0.3-10000 nM), then 
incubated for 7-14 days for colony formation. After this incubation period, the 
colonies were fixed, stained, washed in tap water, air-dried, and counted. To 
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determine the equivalent concentration of each inhibitor for 50% cell kill (EC50), the 
surviving fractions (SF) were plotted as a function of log(inhibitor concentration) and 
were fitted to a 4-parameter logistic equation of the form:  
 
𝑆𝐹 = 𝐵 +
𝑇−𝐵
{1−10[(𝑙𝑜𝑔𝐸𝐶50−𝐷)𝐻𝑆}
    (2.2), 
 
where B and T are the minimum and maximum of the sigmoidal curve, respectively, 
D is the log(inhibitor concentration), and HS is the steepest slope of the curve. Three 
independent experiments were performed for each cell line and dose point. 
 
2.8. Evaluation of Therapeutic Potential 
 
To assess whether the various treatment protocols (X-rays or inhibitors) used in this 
study had a potential therapeutic benefit, a relative sensitivity (RS) was determined. 
For this, the D50 and EC50 of the normal cell lines (L132 for lung; MCF-12A for breast 
and cervix) were compared with those for the respective tumour cell lines (A549 for 
lung; MDA-MB-231, MCF-7, HeLa for breast and cervix), according to Maleka et al., 
(2019), as follows: 
 
𝑅𝑆 =
𝐷50(𝑛𝑜𝑟𝑚𝑎𝑙)
𝐷50(𝑡𝑢𝑚𝑜𝑢𝑟)
  𝑜𝑟 
𝐸𝐶50(𝑛𝑜𝑟𝑚𝑎𝑙)
𝐸𝐶50(𝑡𝑢𝑚𝑜𝑢𝑟)
       (2.3). 
 
The criteria for potential therapeutic benefit, no potential benefit, and no potential 
benefit with possible undesirable effects of each agent are RS>1.0, RS=1.0 and 
RS<1.0, respectively. 
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2.9. Effect of Inhibitors on Radiation Response    
 
Radiosensitisation induced by inhibitors, AG-1478, NVP-BEZ235 and ABT-263, 
added 30 minutes prior to irradiation was assessed by clonogenic assay in each cell 
line. Cells were seeded in 5 or 10 ml of cell line specific medium at numbers ranging 
from 200-8000 per 25 cm2 flask. The flasks were incubated at 37ºC for 4-5 hours to 
allow the cells to settle before administration of a corresponding EC50 dose of 
inhibitor, as determined in Section 2.7, followed by exposure to a dose of X-rays 
ranging from 2-8 Gy. The flasks were then re-incubated until colony formation had 
occurred. Exposure to the inhibitor was for the duration of the experiment. After an 
incubation period of 7-14 days, colonies were fixed, stained, and counted. The 
corresponding surviving fractions were calculated. Unirradiated cell cultures, with 
and without inhibitors, served as controls. Three independent experiments were 
performed for each cell line and dose point.  
 
The modulatory effect of inhibitors on radiosensitivity was expressed as a survival 
modifying factor (MFsurvival), given as the ratio of the mean inactivation dose (?̅?) in the 
absence and presence of inhibitor: 
 
𝑀𝐹𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 =
?̅?(𝑋−𝑟𝑎𝑦𝑠)
?̅?(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟+𝑋−𝑟𝑎𝑦𝑠)
       (2.4). 
 
The criteria for inhibition, no effect, and enhancement of radiosensitivity by inhibitors 
are MF<1.0, MF=1.0, and MF>1.0, respectively.  
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2.10. Inhibitor Interaction 
 
To test for potential interaction between inhibitors, the toxicity data obtained in 
Section 2.7 were fitted to the function:  
 
log(fa/fu) = m×log(D) – m×log(Dm)   (2.5), 
 
where fa and fu are the affected and unaffected fractions of cells, respectively, to 
generate median-effect plots for each inhibitor. D is the concentration of inhibitor, Dm 
is the median-effect concentration of inhibitor, and the coefficient m is an indicator of 
the shape of the inhibitor concentration-effect relationship (Chou, 2006; Hamunyela 
et al., 2017). The shape parameter m = 1, >1, and <1 for hyperbolic, sigmoidal, and 
flat-sigmoidal inhibitor concentration-effect curves, respectively. 
 
The mode of interaction between any two inhibitors was assessed by determining 
combination indices (CI) for each inhibitor cocktail from the fitted parameters of 
equation (2.3) according to the equation: 
 
𝐶𝐼 =
𝐷1
{𝐷𝑚1×(
𝑓𝑎1
1−𝑓𝑎1
)
1
𝑚1}
+  
𝐷2
{𝐷𝑚2×(
𝑓𝑎2
1−𝑓𝑎2
)
1
𝑚2}
   (2.6), 
 
 where D1 is the concentration of Inhibitor 1 and D2 is the concentration of Inhibitor 2. 
m1 and m2 are the respective shape parameters. fa1 and fa2 are given as: (1 – SF, as 
defined in equation (2.2)). Dm1 and Dm2 are the corresponding median-effect 
concentrations. Synergism, additivity, and antagonism are indicated by CI < 1, CI = 
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1, and CI > 1, respectively. Furthermore, the criteria for very strong synergism, 
strong synergism, and synergism are CI < 0.1, 0.1 ≤ CI ≤ 0.3, 0.3 < CI ≤ 0.7, 
respectively (Chou, 2006). 
 
2.11. MTT Assay 
 
The  3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was 
used to determine the effect of the various treatment protocols used in this study on 
the metabolic activity of the MCF-7, MDA-MB-231, MCF-12A, HeLa, L132 and A549 
cell lines. 
 
For this, cells were seeded in quadruplicate in 96-well plates (Corning, USA), that 
had been treated for cell culture, at 100 000 cells per well and incubated at 37ºC for 
4-5 hours. After incubation, the cells were either given a 2-Gy dose of X-rays (a 
clinically relevant single fraction), or treated with an EC50 concentration of inhibitor, 
or a combination of inhibitors, or a combination of an EC50 concentration of inhibitor 
and irradiation. After treatment, the cells were incubated for 0.5, 2, 24, and 52 hours. 
These time points were chosen in order to assess early, intermediate, and late 
changes in cellular metabolism. After incubation, 100 µl of MTT (Sigma, USA, cat # 
M2128) (dissolved in PBS to a concentration of 50 mg/ml) was added to each well in 
a darkened laminar flow cabinet, whereupon the plates were wrapped in foil and re-
incubated at 37ºC for 4 hours. One hundred microlitres of DMSO was added to each 
well, and the absorbances (optical densities, OD; blank subtracted) read at 570 nm 
on a microplate spectrophotometer (Labtech International, Sussex, UK; Model #: LT-
4000) ten minutes later as a measure of metabolic activity.  
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The mean absorbances in samples treated with X-rays only were compared to those 
obtained for the growth medium controls (OD2Gy/ODmedium) to give radiation induced 
relative metabolic activities. Similarly, the ratios of mean absorbances in samples 
treated with combinations of X-rays and inhibitors to those obtained for the inhibitor 
controls (OD2Gy+inhibitor/ODinhibitor) were determined as combination treatment induced 
relative metabolic activity. The ratios of the former to the latter (or modifying factors) 
were then derived to represent the mode by which the inhibitors modified metabolic 
activity in irradiated cells. The criteria for a reduction, no effect, and an enhancement 
in metabolic activity in irradiated cells by inhibitors are MF>1, MF=1, and MF<1, 
respectively.   
 
 
2.12. Data Analysis 
 
Statistical analysis and data fitting were performed by means of GraphPad Prism 
(GraphPad Software, San Diego, USA). The unpaired two-sided Student’s t-test was 
used to compare two data sets. A P < 0.05 indicates a statistically significant 
difference between the data sets. Data were presented as the mean ± SEM of three 
independent experiments. Where necessary, errors were determined using 
appropriate error propagation formulae. For associations, linear regression analyses 
were used. 
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CHAPTER 3 
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3. RESULTS 
 
3.1. Intrinsic Radiosensitivity 
 
Figure 3.1 shows the resultant cell survival curves for three human breast cell lines 
(MDA-MB-231, MCF-7 and MCF-12A), following X-ray exposure. To evaluate the 
intrinsic radiosensitivity of these cell lines, the surviving fraction at 2 and 6 Gy (SF2 
and SF6), the dose at which 50% of the cell population is killed (D50), and the area 
under the curve (?̅?) were extrapolated from these survival curves and summarised in 
Table 3.1. 
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Figure 3.1: Clonogenic cell survival curves for 3 human breast cell lines after X-ray irradiation. 
Symbols represent the mean surviving fraction ± SEM from three independent experiments. Survival 
curves were obtained by fitting experimental data to the linear-quadratic model. The dose at which 
50% of cells survive (D50) is the dose at which each survival curve intersects the horizontal dashed 
line. 
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Based on all parameters, the rank order of increasing radiosensitivity in the breast 
cell lines was found to be MCF-12A<MDA-MB-231<MCF-7.  
 
Table 3.1: Summary of radiobiological parameters for the 6 human cell lines. SF2 and SF6 denote the 
surviving fraction at 2 and 6 Gy, respectively. ?̅? denotes the mean inactivation dose (area under the 
cell survival curve). D50 the radiation absorbed dose for 50% cell killing. Data are presented as the 
mean ± SEM from 3 independent experiments. 
 Cell Lines SF2 SF6 D50 (Gy) 𝑫 (Gy) 
MDA-MB-231 0.28±0.02 0.010±0.003 1.14±0.07 1.93±0.03 
MCF-7 0.17±0.03 0.003±0.000* 0.82±0.11 1.33±0.13 
MCF-12A 0.52±0.04 0.067±0.001 2.11±0.09 2.56±0.11 
HeLa 0.33±0.07 0.040±0.000* 1.24±0.03 1.95±0.03 
A549 0.54±0.05 0.068±0.01 2.20±0.23 2.87±0.05 
L132 0.67±0.06 0.066±0.03 2.79±0.26 3.11±0.03 
*errors less than 0.001. 
 
The survival curves for the two human lung cell lines (L132 and A549) and a cervical 
carcinoma cell line (HeLa) are shown in Figure 3.2. The cervical cancer cell line was 
more radiosensitive at doses less 8 Gy, but shows higher radioresistance at doses 
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greater than 8 Gy. Overall, the parameters ranked these cell lines in order of   
increasing radiosensitivity as HeLa<A549<L132 (Table 3.1). 
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Figure 3.2: Clonogenic cell survival curves for 2 lung cell lines and a cervical cancer cell line after X-
ray irradiation. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments. Survival curves were obtained by fitting experimental data to the linear-quadratic model. 
The dose at which 50% of cells survive (D50) is the dose at which each survival curve intersects the 
horizontal dashed line. 
 
 
Given the inconsistency in radiosensitivity ranking when a single radiobiological 
parameter is used, it is necessary to consider using multiple parameters to obtain a 
more representative reflection of relative cellular radiosensitivity. For this, a rank 
order was constructed based on SF2, SF6, D50, and 𝐷,̅  as presented in Table 3.2. 
Using the frequency of occurrence of each cell line under each rank, the cell lines 
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may be arranged in order of increasing radiosensitivity as: L132  A549  MCF-
12A  HeLa  MDA-MB-231  MCF-7. 
 
Table 3.2:  Arrangement of the studied panel of cell lines from most radioresistant to most 
radiosensitive, according to the extrapolated parameters. 
 
Parameters 
 
 
Increasing Radiosensitivity 
 
 
SF2 L132 A549 MCF-12A HeLa MDA-MB-231 MCF-7 
SF6 A549 L132 MCF-12A HeLa MDA-MB-231 MCF-7 
D50 L132 A549 MCF-12A HeLa MDA-MB-231 MCF-7 
𝑫 L132 A549 MCF-12A HeLa MDA-MB-231 MCF-7 
 
 
 
3.2. Therapeutic Potential of X-rays 
 
To determine whether treatment of the cancer cell lines with X-rays has a potential 
therapeutic benefit, the relative sensitivities (RS), as described in Section 2.8, were 
determined on the basis of the D50-values.  The data presented in Table 3.3 
summarise the relative radiosensitivities of the tumour cells. The RS-values in Table 
3.3 suggest that potential therapeutic benefit may be derived from treating MDA-MB-
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231, MCF-7, HeLa and A549 cells with X-rays. MCF-7 showed the highest potential 
of therapeutic benefit with a greater than 2-fold relative sensitivity. The lung cancer 
cell line, A549, showed the lowest potential for therapeutic benefit.   
 
Table 3.3: Summary of D50-values for 3 human breast cell lines (normal: MCF-12A; cancer: MCF-7, 
MDA-MB-231), 2 human lung cell lines (normal: L132; cancer: A549), and a cervical cancer cell line 
(HeLa). Their relative radiosensitivities (RS), determined by clonogenic cell survival, after exposure to 
X-rays (Equation 2.3). RS-values were derived by comparing the D50-values of the normal cell lines 
(MCF-12A and L132) to those of the tumour cell lines (MCF-7 and MDA-MB-231) and (A549 and 
HeLa), respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
*Errors were calculated using error propagation formulae for ratios. 
 
 
  
Cell Line D50 (Gy) RS* 
MCF-12A 2.11±0.09 − 
MDA-MB-231 1.14±0.07 1.85 ± 0.13 
MCF-7 0.82±0.11 2.57 ± 0.37 
L132 2.79±0.26 - 
A549 2.20±0.23 1.27 ± 0.18 
HeLa 1.24±0.03 1.70 ± 0.08 
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3.3. Inhibitor Cytotoxicity  
 
3.3.1. Cytotoxicity of AG-1478, NVP-BEZ235 and ABT-263 in Breast Cell Lines 
 
Treating the human breast cell lines with inhibitors induced a concentration-
dependent cell kill (Figure 3.3-3.5). From these sigmoidal graphs and summary of 
data in Table 3.4, NVP-BEZ235 emerged as more potent than ABT-263 and AG-
1478 in all cell lines. The least toxic of this inhibitor panel was observed to be AG-
1478.  
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Figure 3.3: Cytotoxicity curves for an EGFR inhibitor (AG-1478), a PI3K and mTOR inhibitor (NVP-
BEZ235), and a Bcl-2 inhibitor (ABT-263) for the triple negative human breast cancer cell line, MDA-
MB-231. Curves were obtained by plotting the cell survival as a function of log(inhibitor 
concentration). Cell survival was determined by the colony assay, and data were fitted to a 4-
parameter logistic equation. Data points are means ± SEM of 3 independent experiments. The log of 
the concentration at which 50% of cells survive (EC50) is that at which each survival curve intersects 
the horizontal dashed line (as indicated by the red arrow). 
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The equivalent concentrations of NVP-BEZ235, ABT-263 and AG-1478 for 50% cell 
survival for the MDA-MB-231 cell line were found to be 108.2 ± 6.90, 2212 ± 246, 
and 7895 ± 826 nM, respectively. The corresponding EC50-values for the MCF-7 cell 
line emerged as 16.90 ± 0.69, 1217 ± 227, and 3466 ± 259 nM. Treatment of the 
apparently normal human breast cell line MCF-12A with NVP-BEZ235, ABT-263, 
and AG-1478 yielded EC50-values of 26.19 ± 3.35, 1157 ± 86 and 8185 ± 474 nM, 
respectively. 
 
Table 3.4: Summary of cytotoxicity data for 3 human breast cell lines (MDA-MB-231, MCF-7 and 
MCF-12A) treated with EGFR inhibitor (AG-1478), PI3K and mTOR inhibitor (NVP-BEZ235), and Bcl-
2 inhibitor (ABT-263). EC50 denotes the equivalent concentration for 50% cell survival. T and B are 
the maximum and minimum of the concentration-response curve, respectively (Figures 3.3-3.5). HS is 
the steepest slope of the curve. 
Cell line Treatment EC50 (nM)  T B HS 
 
MDA-MB-231 
AG-1478 7895±826  0.99±0.02  -0.01±0.02  -1.13±0.11  
NVP-BEZ235 108.2±6.9 0.98±0.02 -0.01±0.02 -1.78±0.18 
ABT-263  2212±246  0.98±0.01  -0.01±0.02  -1.16±0.11  
 
MCF-7 
AG-1478 3466±259  0.98±0.02  -0.02±0.02  -1.59±0.18  
NVP-BEZ235 16.90±0.69 1.01±0.01 0.01±0.01 -2.25±0.02 
ABT-263  1217±227 1.01±0.03  -0.02±0.03  -0.80±0.11  
 
MCF-12A 
AG-1478 8185±474 0.99±0.01  -0.01±0.01  -1.93±0.14  
NVP-BEZ235 26.19±3.35    1.01±0.03 -0.01±0.03 -1.32±0.17 
ABT-263  1157±86 0.99±0.00  0.00±0.01  -3.61±1.77  
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Figure 3.4: Cytotoxicity curves for an EGFR inhibitor (AG-1478), a PI3K and mTOR inhibitor (NVP-
BEZ235), and a Bcl-2 inhibitor (ABT-263) for the luminal A subtype human breast cancer cell line, 
MCF-7. Curves were obtained by plotting the cell survival as a function of log(inhibitor concentration). 
Cell survival was determined by the colony assay, and data were fitted to a 4-parameter logistic 
equation. Data points are means ± SEM of 3 independent experiments. The log of the concentration 
at which 50% of cells survive (EC50) is that at which each survival curve intersects the horizontal 
dashed line (as indicated by red red arrow). 
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Figure 3.5: Cytotoxicity curves for an EGFR inhibitor (AG-1478), a PI3K and mTOR inhibitor (NVP-
BEZ235), and a Bcl-2 inhibitor (ABT-263) for an apparent normal human breast cell line, MCF-12A. 
Curves were obtained by plotting the cell survival as a function of log(inhibitor concentration). Cell 
survival was determined by the colony assay, and data were fitted to a 4-parameter logistic equation. 
Data points are means ± SEM of 3 independent experiments. The log of the concentration at which 
50% of cells survive (EC50) is that at which each survival curve intersects the horizontal dashed line 
(as indicated by the red arrow). 
 
 
3.3.2. Cytotoxicity of AG-1478, NVP-BEZ235 and ABT-263 in Lung and Cervix 
Cell Lines 
 
Inhibition of EGFR, PI3K/mTOR, and Bcl-2 with AG-1478, NVP-BEZ235, and ABT-
263, respectively, also yielded a concentration-dependent cell kill in the A549, L132 
and HeLa cell lines (Figures 3.6-3.8). These figures and summarised data in Table 
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3.5 also indicate that NVP-BEZ235 is the most toxic inhibitor in these cell lines and 
that AG-1478 had the least cytotoxic effect.  
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Figure 3.6: Cytotoxicity curves for an EGFR inhibitor (AG-1478), a PI3K and mTOR inhibitor (NVP-
BEZ235), and a Bcl-2 inhibitor (ABT-263) for the human cervical carcinoma cell line, HeLa. Curves 
were obtained by plotting the cell survival as a function of log(inhibitor concentration). Cell survival 
was determined by the colony assay, and data were fitted to a 4-parameter logistic equation. Data 
points are means ± SEM of 3 independent experiments. The log of the concentration at which 50% of 
cells survive (EC50) is that at which each survival curve intersects the horizontal dashed line (as 
indicated by the red arrow). 
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Table 3.5: Summary of cytotoxicity data for 2 human lung cell lines (A549 and L132) and a cervix 
carcinoma cell line (HeLa) treated with EGFR inhibitor (AG-1478), PI3K and mTOR inhibitor (NVP-
BEZ235), and Bcl-2 inhibitor (ABT-263). EC50 denotes the equivalent concentration for 50% cell 
survival. T and B are the maximum and minimum of the concentration-response curve, respectively 
(Figures 3.6-3.8). HS is the steepest slope of the curve. 
 
 
The EC50-values for HeLa emerged as 1096 ± 287, 0.50 ± 0.06, and 1027 ± 146 nM 
for AG-1478, NVP-BEZ235, and ABT-263 treatment, respectively. The 
corresponding EC50-values for the human lung carcinoma cell line, A549, were found 
to be 5485 ± 485, 15.23 ± 1.16, and 2161 ± 189 nM. For the normal lung cell line, 
L132, the EC50-values were 8934 ± 332, 114 ± 6.36, and 1599 ± 178 nM, after 
treatment with AG-1478, NVP-BEZ235, and ABT-263, respectively. 
 
 
 
 
Cell line Treatment EC50 (nM)  T B HS 
 
HeLa 
AG-1478 1096±287  1.02±0.02  -0.05±0.05  -0.55±0.07  
NVP-BEZ235 0.50±0.06 1.01±0.03 0.00±0.01 -0.91±0.08 
ABT-263  1027±146 0.98±0.01 -0.03±0.02  -0.87±0.09  
 
A549 
AG-1478 5458±485  0.99±0.02  -0.02±0.02  -1.63±0.21  
NVP-BEZ235 15.23±1.16 0.99±0.01 -0.02±0.02 -1.13±0.08 
ABT-263  2161±189  0.99±0.01  0.00±0.01  -1.89±0.19  
 
L132 
AG-1478 8934±332 0.99±0.01  0.01±0.02  -4.19±0.73 
NVP-BEZ235 114±6.36    0.99±0.01 0.01±0.02 -2.43±0.30 
ABT-263  1599±178 0.99±0.01  0.00±0.02  -1.26±0.17  
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Figure 3.7: Cytotoxicity curves for an EGFR inhibitor (AG-1478), a PI3K and mTOR inhibitor (NVP-
BEZ235), and a Bcl-2 inhibitor (ABT-263) for the human lung cancer cell line, A549. Curves were 
obtained by plotting the cell survival as a function of log(inhibitor concentration). Cell survival was 
determined by the colony assay, and data were fitted to a 4-parameter logistic equation. Data points 
are means ± SEM of 3 independent experiments. The log of the concentration at which 50% of cells 
survive (EC50) is that at which each survival curve intersects the horizontal dashed line (as indicated 
by the red arrow). 
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Figure 3.8: Cytotoxicity curves for an EGFR inhibitor (AG-1478), a PI3K and mTOR inhibitor (NVP-
BEZ235), and a Bcl-2 inhibitor (ABT-263) for an apparent normal human lung cell line, L132. Curves 
were obtained by plotting the cell survival as a function of log(inhibitor concentration). Cell survival 
was determined by the colony assay, and data were fitted to a 4-parameter logistic equation. Data 
points are means ± SEM of 3 independent experiments. The log of the concentration at which 50% of 
cells survive (EC50) is that at which each survival curve intersects the horizontal dashed line (as 
indicated by the red arrow). 
 
3.4. Therapeutic Potential of Inhibitors 
 
To evaluate the existence of a potential therapeutic benefit when the cell lines are 
treated with the specified inhibitors, relative sensitivities (RS), as described in 
Section 2.8, were determined on the basis of the EC50-values. The data presented in 
Table 3.6 summarise the relative sensitivities of the tumour cells.  
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Table 3.6: Summary of EC50-values for 3 human breast cell lines (normal: MCF-12A; cancer: MCF-7, 
MDA-MB-231), 2 human lung cell lines (normal: L132; cancer: A549), and a cervical cancer cell line 
(HeLa). Their relative radiosensitivities (RS), determined by clonogenic cell survival, after exposure to 
X-rays (Equation 2.3). RS-values were derived by comparing the EC50-values of the normal cell lines 
(MCF-12A and L132) to those of the tumour cell lines (MCF-7 and MDA-MB-231) and (A549 and 
HeLa), respectively. 
*Errors were calculated using error propagation formulae for ratios. 
 
Cell line Treatment EC50 (nM) RS* 
 
MCF-12A 
AG-1478 8185 ± 474 -  
NVP-BEZ235 26.19 ± 3.35    - 
ABT-263  1157 ± 86 -  
 
MDA-MB-231 
AG-1478 7895 ± 826  1.04 ± 0.12 
NVP-BEZ235 108 ± 7 0.24 ± 0.04 
ABT-263  2212 ± 246  0.52 ± 0.07 
 
MCF-7 
AG-1478 3466 ± 259  2.36 ± 0.22 
NVP-BEZ235 16.90 ± 0.69 1.62 ± 0.22 
ABT-263  1217 ± 227 0.95 ± 0.19 
 
L132 
AG-1478 8934 ± 332 -  
NVP-BEZ235 114 ± 6    - 
ABT-263  1599 ± 178 -  
 
A549 
AG-1478 5458 ± 485  1.67 ± 0.16 
NVP-BEZ235 15.23 ± 1.16 7.48 ± 0.71 
ABT-263  2161 ± 189  0.74 ± 0.11 
 
HeLa 
AG-1478 1096 ± 287  7.47 ± 2.00 
NVP-BEZ235 0.50 ± 0.06 52.38 ± 9.19 
ABT-263  1027 ± 146 1.13 ± 0.18 
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EGFR inhibition (using AG-1478), yielded relative sensitivities of equal to or greater 
than 1.0, indicating that such treatment results in a therapeutic benefit or no effect.  
 
Inhibition of PI3K and mTOR with NVP-BEZ235 results in a huge therapeutic benefit 
for the lung and cervical cancer cell lines, a slight benefit in the MCF-7 cell line, and 
no benefit (with potential harmful effects) for the MDA-MB-231 cell line.  
 
Bcl-2 inhibition with ABT-263 has either no effect (MDA-MB-231 and A549) or results 
in potential harmful effects (MCF-7 and HeLa).  
 
 
3.5. Mode of Inhibitor Action in Cells and Inhibitor Interaction 
 
To determine the nature of cellular response to treatment with the EGFR, 
PI3K/mTOR, and Bcl-2 inhibitors in the cell lines, the cell survival data presented in 
Figures 3.3-3.8 were log transformed as described in Section 2.10, to obtain median-
effect plots for the inhibitors.  
 
3.5.1. Inhibitor Interaction in the MDA-MB-231, MCF-7, and MCF-12A Cell Lines 
 
Figure 3.9 represents the median-effect plots for the MDA-MB-231 cell line. The Bcl-
2, EGFR, and PI3K/mTOR inhibitors seem to have different modes of interaction with 
these cells, as the slopes of the curves emerged as 0.73, 1.08, and 1.36, indicating 
flat-sigmoidal, hyperbolic, and sigmoidal concentration-effects, respectively (Table 
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3.7). The corresponding median-effect concentrations (Dm) were ~145, 5332, and 
1543 nM. 
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Figure 3.9: Median-effect plots (Section 2.10) for the triple negative human breast cancer cell line 
(MDA-MB-231), treated with AG-1478, NVP-BEZ235, and ABT-263, from toxicity data presented in 
Figure 3.3. Horizontal dashed line is the median-effect axis.  
 
 
The median-effect plots for the MCF-7 cell line are presented in Figure 3.10. While 
inhibition of Bcl-2 in these cells with ABT-263 yielded a shallow median-effect curve 
with a slope of 0.95 (flat-sigmoidal), inhibition of EGFR and PI3K/mTOR resulted in 
steeper curves with slopes of 1.67 and 1.33, respectively (Table 3.6). Therefore, 
cytotoxicity of AG-1478 and NVP-BEZ235 in these cells follow a sigmoidal pattern. 
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The Dm-values for NVP-BEZ235, ABT-263, and AG-1478 were ~18, 1300, and 2916 
nM, respectively.  
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Figure 3.10: Median-effect plots (Section 2.10) for the luminal A human breast cancer cell line (MCF-
7), treated with AG-1478, NVP-BEZ235, and ABT-263, from toxicity data presented in Figure 3.4. 
Horizontal dashed line is the median-effect axis.  
 
 
Figure 3.11 represents the median-effect plots for the apparently normal breast cell 
line (MCF-12A). In these cells, inhibition of PI3K/mTOR, Bcl-2, and EGFR follows a 
sigmoidal pattern, with the slopes of the median-effect curves emerging as 1.33, 
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2.69, and 1.67, respectively (Table 3.6). The median-effect concentrations of 
respective inhibitors were found to be ~26, 606, and 4268 nM. 
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Figure 3.11: Median-effect plots (Section 2.10) for the apparently normal human breast cell line 
(MCF-12A), treated with AG-1478, NVP-BEZ235, and ABT-263, from toxicity data presented in Figure 
3.5. Horizontal dashed line is the median-effect axis.  
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Table 3.7: Summary of parameters of median-effect plots for EGFR inhibitor (AG-1478), PI3K and 
mTOR inhibitor (NVP-BEZ235), and Bcl-2 inhibitor (ABT-263) in 3 human breast cell lines (MDA-MB-
231, MCF-7 and MCF-12A).  
 
 
The potential mode of interaction between the panel of inhibitors in the breast cell 
lines, used in this study, was interrogated using combination indices (CI) obtained 
from the fitted parameters of the median-effect plots (Figures 3.9-3.11), as defined 
under Section 2.10. For each cocktail treatment of MDA-MB-231, CI-values were 
significantly less than 0.1 (Table 3.8), indicating very strong synergism between 
inhibitors when combined at EC50 concentrations. Inhibitor cocktail treatment of 
MCF-7 cells produced combination indices ranging from 0.0585 to 0.1351, indicating 
that inhibitor-inhibitor interaction varied from synergism to strong synergism. 
Similarly, mild to strong synergism emerged between inhibitors in the apparently 
Cell line Treatment m  Dm (nM) Shape of 
concentration-
effect curve 
 
MDA-MB-231 
AG-1478 1.08 ± 0.15  5332 ± 6  hyperbolic 
NVP-BEZ235 1.36 ± 0.29 144.93 ± 3.01 sigmoidal 
ABT-263  0.73 ± 0.09 1543 ± 4 flat-sigmoidal 
 
MCF-7 
AG-1478 1.46 ± 0.09  2916 ± 3  sigmoidal 
NVP-BEZ235 1.89 ± 0.12 17.79 ± 0.35 sigmoidal 
ABT-263  0.95 ± 0.08 1300 ± 3 flat-sigmoidal 
 
MCF-12A 
AG-1478 1.67 ± 0.11 4268 ± 3 sigmoidal 
NVP-BEZ235 1.33 ± 0.14    26.11 ± 0.70   sigmoidal 
ABT-263  2.69 ± 0.38 606 ± 4 sigmoidal 
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normal breast cell line (MCF-12A), with combination indices ranging between 0.1553 
and 0.4683.  
 
 
Table 3.8: Summary of combination indices for EGFR inhibitor (AG-1478), PI3K and mTOR inhibitor 
(NVP-BEZ235), and Bcl-2 inhibitor (ABT-263), when used concurrently at their respective EC50 
concentrations in 3 human breast cell lines (MDA-MB-231, MCF-7 and MCF-12A).  
 
 
3.5.2. Inhibitor Interaction in the HeLa, A549, and L132 Cell Lines 
 
Figure 3.12 represents the median-effect plots for the HeLa cell line. While the 
inhibition of EGFR and Bcl-2 in these cells followed a flat sigmoidal pattern with 
slopes of 0.86 and 0.74, respectively, inhibiting PI3K/mTOR yielded a hyperbolic 
response with a slope of 1.00 (Table 3.9). The median-effect concentrations (Dm) 
Cell line Agent 1 
Agent 2 
AG-1478    NVP-BEZ235 ABT-263 
 
MDA-MB-231 
AG-1478 -  0.0465 0.0237 
NVP-BEZ235 0.0465 - 0.0281 
ABT-263  0.0237 0.0281 - 
 
MCF-7 
AG-1478 -  0.1351 0.0585 
NVP-BEZ235 0.1351 - 0.0914 
ABT-263  0.0585 0.0914 - 
 
MCF-12A 
AG-1478 - 0.1553 0.4683 
NVP-BEZ235 0.1553 - 0.3788 
ABT-263  0.4683 0.3788 - 
Stellenbosch University https://scholar.sun.ac.za
69 
 
following treatment of these cells with AG-1478, NVP-BEZ235, and ABT-263 were 
~856, 0.49, and 538 nM, respectively.     
 
-2 -1 1 2 3 4 50
-4
-3
-2
-1
0
1
2
3
AG-1478
NVP-BEZ235
HeLa
ABT-263
log[inhibitor, nM]
lo
g
(f
a
/f
u
)
 
Figure 3.12: Median-effect plots (Section 2.10) for the human cervical carcinoma cell line (HeLa), 
treated with AG-1478, NVP-BEZ235, and ABT-263, from toxicity data presented in Figure 3.6. 
Horizontal dashed line is the median-effect axis.  
 
 
The median-effect plots for the lung cancer cell line (A549) are shown in Figure 3.13. 
Inhibition of EGFR in these cells with AG-1478 yielded a sigmoidal median-effect plot 
with a slope of 1.64, while the inhibition of PI3K/mTOR and Bcl-2 produced shallower 
(flat-sigmoidal) median-effect plots with slopes of ~0.84 and 0.91, respectively (Table 
3.9). The corresponding median-effect concentrations (Dm) were ~ 6251, 17.15, and 
816 nM. 
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Figure 3.13: Median-effect plots (Section 2.10) for the human lung cancer cell line (A549), treated 
with AG-1478, NVP-BEZ235, and ABT-263, from toxicity data presented in Figure 3.7. Horizontal 
dashed line is the median-effect axis.  
 
 
Figure 3.14 depicts the median-effect plots of apparently normal lung cell line, L132. 
The response of these cells to EGFR, PI3K/mTOR and Bcl-2 inhibition followed 
similar patterns as seen in the A549 cell line, with the slopes of the median-effect 
plots emerging as 1.70, 0.87, and 0.70, respectively (Table 3.9). The median-effect 
concentrations for the respective inhibitors were found to be 8396, 79.97, and 798 
nM. 
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Figure 3.14: Median-effect plots (Section 2.10) for the apparently normal human lung cell line (L132), 
treated with AG-1478, NVP-BEZ235, and ABT-263, from toxicity data presented in Figure 3.8. 
Horizontal dashed line is the median-effect axis.  
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Table 3.9:  Summary of parameters of median-effect plots for EGFR inhibitor (AG-1478), PI3K and 
mTOR inhibitor (NVP-BEZ235), and Bcl-2 inhibitor (ABT-263) in 2 human lung cell lines (A549 and 
L132) and a cervix carcinoma cell line (HeLa).  
 
 
The mode of interaction between the panel of inhibitors in the cervical and lung cell 
lines was also assessed using combination indices, when the inhibitors were 
combined at EC50 concentrations. While a cocktail of AG-1478 and ABT-263 showed 
very strong synergism in HeLa cells (CI = 0.01), a strong antagonism (CI  4.1) 
emerged for a cocktail of AG-1478 and NVP-BEZ235 (Table 3.10). For the A549 cell 
line, all cocktail treatments showed very strong inhibitor-inhibitor interactions, with 
combination indices ranging from ~0.02 to 0.07. Similarly, a very strong synergism 
emerged between inhibitors in the apparently normal lung cell line, L132 (0.0101  
CI  0.0785). 
 
Cell line Treatment m  Dm (nM) Shape of 
concentration-
effect curve 
 
HeLa 
AG-1478 0.86 ± 0.11  856 ± 4  flat-sigmoidal 
NVP-BEZ235 1.00 ± 0.08 0.49 ± 0.05 hyperbolic 
ABT-263  0.74 ± 0.08 538 ± 3 flat-sigmoidal 
 
A549 
AG-1478 1.64 ± 0.30  6251 ± 8 sigmoidal 
NVP-BEZ235 0.84 ± 0.07 17.15 ± 0.35 flat-sigmoidal 
ABT-263  0.91 ± 0.08 816 ± 2 flat-sigmoidal 
 
L132 
AG-1478 1.70 ± 0.31 8396 ± 9 sigmoidal 
NVP-BEZ235 0.87 ± 0.10    79.97 ± 1.16 flat-sigmoidal 
ABT-263  0.70 ± 0.09 798 ± 3 flat-sigmoidal 
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Table 3.10: Summary of combination indices for EGFR inhibitor (AG-1478), PI3K and mTOR inhibitor 
(NVP-BEZ235), and Bcl-2 inhibitor (ABT-263), when used concurrently at their respective EC50 
concentrations in 2 human lung cell lines (A549 and L132) and a cervix carcinoma cell line (HeLa). 
 
 
 
3.6. Radiomodulation by Inhibitors 
 
To evaluate the radiomodulatory effects of the EGFR, PI3K/mTOR, and Bcl-2 
inhibitors in the cell lines employed in this study, cell survival data were fitted to the 
linear-quadratic model, as described in Section 2.5. Mean activation doses (?̅?) were 
obtained and used to derive modifying factors, defined in Equation 2.4. The mean 
inactivation dose was selected for this assessment, as some of the cell survival 
curves (especially those from inhibitor treatment) tended to turn upward at higher X-
ray doses, indicating some radioprotection. With such a peculiarity in survival curves, 
Cell line Agent 1 
Agent 2 
AG-1478    NVP-BEZ235 ABT-263 
 
HeLa 
AG-1478 -  4.0835 0.0100 
NVP-BEZ235 4.0835 - 4.0812 
ABT-263  0.0100 4.0812 - 
 
A549 
AG-1478 -  0.0581 0.0700 
NVP-BEZ235 0.0581 - 0.0221 
ABT-263  0.0700 0.0221 - 
 
L132 
AG-1478 - 0.0785 0.0741 
NVP-BEZ235 0.0785 - 0.0101 
ABT-263  0.0741 0.0101 - 
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cell survival at a single low or high dose (e.g. SF2 or SF6) would not be a reliable 
representation of the overall radiosensitivity of a particular cell line. 
 
3.6.1.  Radiomodulation in the MCF-12A, MDA-MB-231, and MCF-7 Cell Lines  
 
Figure 3.15, represents the survival data of the apparently normal breast cell line 
(MCF-12A) after inhibitor and X-ray treatment.  
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Figure 3.15: Cell survival curves for the apparently normal human breast cell line (MCF-12A) after X-
ray irradiation. Cells were irradiated without or in the presence of AG-1478 (AG), NVP-BEZ235 (BEZ), 
and ABT-263 (ABT), administered either singly or in combination. Symbols represent the mean 
surviving fraction ± SEM from three independent experiments. 
 
A decrease in cell survival was observed when the inhibitor-pre-treated cells were 
compared to cells treated with X-rays alone. However, these cells appeared to 
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survive better at doses greater than 4 Gy, when pre-treated with AG-1478. The 
mean inactivation dose (?̅?) for the MCF-12A cell line, in this set of experiments, was 
found to be 3.10  0.09 Gy. The modifying factors, based on mean inactivation dose, 
are summarised in Table 3.11. For this cell line, a significant enhancement in 
radiosensitivity emerged when PI3K/mTOR and Bcl-2 were inhibited (0.0080  P  
0.0192). A small, but insignificant, radiosensitisation was seen when the cells were 
pre-treated with AG-1478. Except for the combination of AG-1478 and NVP-BEZ235, 
the radiosensitisation induced by the other inhibitor cocktails in these cells did not 
reach statistical significance.  
 
 
The survival data for the MDA-MB-231 cells are presented in Figure 3.16. Pre-
treatment of these cells with the EGFR inhibitor had no effect on radiosensitivity. A 
general decrease in cell survival was observed when the cells were pre-treated with 
the other inhibitors or inhibitor cocktails. However, at doses greater than 4 Gy, pre-
treatment of the MDA-MB-231 cells with NVP-BEZ235 or a combination of NVP-
BEZ235 and AG-1478 resulted in an increase in cell survival compared to that when 
cells were treated with X-rays alone. This seems to suggest that pre-treating the 
triple negative breast cancer cells with NVP-BEZ235 or an AG-1478/NVP-BEZ235 
cocktail may protect them from the toxic effects of large fractions of radiation, such 
as those used in hyperfractionated regimes. The ?̅? for X-ray treatment alone in this 
cell line, on which inhibitor radiomodulation was based, emerged as 1.77  0.05 Gy.  
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Table 3.11: Modifying factors (MF), relative to X-ray treatment alone, derived from and ?̅? values, as 
described in Section 2.9 for 3 human breast cell lines (normal: MCF-12A; cancer: MCF-7, MDA-MB-
231) irradiated in the presence of AG-1478 (AG), NVP-BEZ235 (BEZ), and ABT-263 (ABT). Errors in 
modifying factors were calculated using error propagation formulae for ratios. 
*Statistically significant difference between X-ray treatment alone and irradiation in the presence of 
inhibitor. 
 
  
Cell line Treatment ?̅? (Gy) P-value MF 
 
MCF-12A 
X-rays + AG 2.81 ± 0.31 0.4738 1.10 ± 0.13 
X-rays + BEZ 1.81 ± 0.08    0.0080* 1.71 ± 0.09    
X-rays + ABT  2.01 ± 0.13 0.0192* 1.54 ± 0.11 
 
MDA-MB-231 
X-rays + AG 1.92 ± 0.12 0.3342 0.92 ± 0.06 
X-rays + BEZ 1.61 ± 0.50 0.7086 1.10 ± 0.34 
X-rays + ABT  1.53 ± 0.25  0.3950 1.16 ± 0.19  
 
MCF-7 
X-rays + AG 1.51 ± 0.06 0.8935 1.01 ± 0.05 
X-rays + BEZ 1.27 ± 0.10 0.0879 1.20 ± 0.10 
X-rays + ABT  1.39 ± 0.03 0.1666 1.09 ± 0.04 
 
MCF-12A 
X-rays + AG + BEZ 1.73 ± 0.14 0.0134* 1.79 ± 0.15 
X-rays + BEZ + ABT 2.33 ± 0.19  0.0662 1.33 ± 0.12 
X-rays + ABT +  AG 2.61 ± 0.14    0.0937 1.19 ± 0.07    
 
MDA-MB-231 
X-rays + AG + BEZ 1.23 ± 0.01  0.0038* 1.44 ± 0.04  
X-rays + BEZ + ABT 1.32 ± 0.06 0.0107* 1.34 ± 0.07 
X-rays + ABT +  AG 1.45 ± 0.13 0.0686 1.22 ± 0.12 
 
MCF-7 
X-rays  + AG + BEZ 1.33 ± 0.05  0.0987 1.14 ± 0.06  
X-rays + BEZ + ABT 1.12 ± 0.03 0.0109* 1.36 ± 0.06 
X-rays + ABT +  AG 1.28 ± 0.01 0.0403* 1.19 ± 0.04 
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Put together, single inhibitor treatment either had no effect or resulted in insignificant 
radiosensitisation in this cell line (Table 3.11). Inhibitor cocktail pre-treatments 
yielded significant radiosensitisation in the MDA-MB-231 cells, except for AG-1478 
and ABT-263 combination. 
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Figure 3.16: Cell survival curves for the triple negative human breast cancer cell line (MDA-MB-231) 
after X-ray irradiation. Cells were irradiated without or in the presence of AG-1478 (AG), NVP-BEZ235 
(BEZ), and ABT-263 (ABT), administered either singly or in combination. Symbols represent the mean 
surviving fraction ± SEM from three independent experiments. 
 
 
Treating MCF-7 cells with AG-1478, NVP-BEZ235, and ABT-263, or a cocktail of 
these inhibitors prior to irradiation appeared to decrease cell survival, when 
compared to MCF-7 cells treated with X-rays alone (Figure 3.17). Treatment of these 
cells with X-rays alone, yield a ?̅?-value of 1.52  0.05 Gy. However, an upward trend 
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in cell survival at higher radiation doses was also observed when cells were treated 
with NVP-BEZ235, an ABT-263/AG-1478 cocktail, or an ABT-263/NVP-BEZ235 
cocktail. In this cell line, significant enhancement in radiosensitivity was observed 
only in ABT-263/NVP-BEZ235 and ABT-263/AG-1478 cocktail pre-treated cell 
cultures (Table 3.11). 
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Figure 3.17: Cell survival curves for the luminal A human breast cancer cell line (MCF-7) after X-ray 
irradiation. Cells were irradiated without or in the presence of AG-1478 (AG), NVP-BEZ235 (BEZ), 
and ABT-263 (ABT), administered either singly or in combination. Symbols represent the mean 
surviving fraction ± SEM from three independent experiments. 
 
 
 
3.6.2.  Radiomodulation in the HeLa, A549, and L132 Cell Lines  
 
Figure 3.18 represents the cell survival curves for apparently normal L132 cells after 
single inhibitor or cocktail treatment prior to irradiation. The mean inactivation dose 
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for these cells was 3.01  0.18 Gy.  Except for the AG-1478 pre-treatment which 
appeared to enhance cell survival relative to X-ray treatment alone, all other inhibitor 
permutations resulted in increased radiosensitivity. Again, an upward trend in cell 
survival was apparent when cells were pre-treated with NVP-BEZ235, an AG-
1478/NVP-BEZ235 cocktail, or an ABT-263/NVP-BEZ235 cocktail (Figure 3.18). 
Taken together, ~3-fold enhancement in radiosensitivity occurred when the L132 
cells were pre-treated with NVP-BEZ235, an AG-1478/NVP-BEZ235 cocktail, or an 
ABT-263/NVP-BEZ235 cocktail (Table 3.12).  
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Figure 3.18: Cell survival curves for the apparently normal human lung cancer cell line (L132) after X-
ray irradiation. Cells were irradiated without or in the presence of AG-1478 (AG), NVP-BEZ235 (BEZ), 
and ABT-263 (ABT), administered either singly or in combination. Symbols represent the mean 
surviving fraction ± SEM from three independent experiments. 
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Table 3.12: Modifying factors (MF), relative to X-ray treatment alone, derived from ?̅? values, as 
described in Section 2.9 for 2 human lung cell lines (A549 and L132) and a cervix carcinoma cell line 
(HeLa) irradiated in the presence of AG-1478 (AG), NVP-BEZ235 (BEZ), and ABT-263 (ABT). Errors 
in modifying factors were calculated using error propagation formulae for ratios.  
*Statistically significant difference between X-ray treatment alone and irradiation in the presence of 
inhibitor. 
 
Cell line Treatment ?̅? (Gy) P-value MF 
 
L132 
X-rays + AG 3.15 ± 0.04 0.5968 0.96 ± 0.06 
X-rays + BEZ 1.02 ± 0.01   0.0034* 2.95 ± 0.18    
X-rays + ABT  2.37 ± 0.36 0.1868 1.27 ± 0.21 
 
HeLa 
X-rays + AG 2.63 ± 0.47 0.5822 0.85 ± 0.16 
X-rays + BEZ 2.04 ± 0.16 0.4421 1.10 ± 0.10 
X-rays + ABT  3.84 ± 0.24  0.0244* 0.59 ± 0.04  
 
A549 
X-rays + AG 2.82 ± 0.05 0.4772 1.04 ± 0.05 
X-rays + BEZ 2.02 ± 0.17 0.0125* 1.45 ± 0.14 
X-rays + ABT  2.85 ± 0.21 0.7613 1.03 ± 0.09 
 
L132 
X-rays + AG + BEZ 1.07 ± 0.01 0.0037* 2.81 ± 0.17 
X-rays + BEZ + ABT 1.01 ± 0.01 0.0034* 2.98 ± 0.18 
X-rays + ABT +  AG 2.54 ± 0.13    0.1010 1.19 ± 0.09    
 
HeLa 
X-rays + AG + BEZ 3.11 ± 0.68  0.4034 0.72 ± 0.16  
X-rays + BEZ + ABT 2.74 ± 0.08 0.0226* 0.82 ± 0.04 
X-rays + ABT +  AG 3.12 ± 0.03 0.0121* 0.72 ± 0.03 
 
A549 
X-rays  + AG + BEZ 2.10 ± 0.34  0.0820 1.39 ± 0.23  
X-rays + BEZ + ABT 1.47 ± 0.03 0.0026* 1.99 ± 0.09 
X-rays + ABT +  AG 2.70 ± 0.14 0.3195 1.08 ± 0.07 
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It is apparent that inhibiting EGFR, PI3K/mTOR and ABT-263 (via single inhibitor or 
cocktail treatment) resulted in an increase in cell survival in the cervical cancer cell 
line (HeLa) after X-ray exposure, when compared with X-ray treatment alone (?̅? = 
2.25  0.09 Gy for X-rays alone; Figure 3.19). However, use of NVP-BEZ235 alone 
either had no effect (at doses up to 4 Gy) or resulted in a mild radiosensitisation at 
higher X-ray doses. In general, pre-treatment of HeLa cells with these inhibitors, 
either singly or in combination, mostly tended to enhance radioresistance, with 
modifying factors ranging between 0.59 and 1.10 (Table 3.12).  
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Figure 3.19: Cell survival curves for the human cervical cancer cell line (HeLa) after X-ray irradiation. 
Cells were irradiated without or in the presence of AG-1478 (AG), NVP-BEZ235 (BEZ), and ABT-263 
(ABT), administered either singly or in combination. Symbols represent the mean surviving fraction ± 
SEM from three independent experiments. 
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The effect of targeting EGFR, PI3K/mTOR and Bcl-2 on A549 cell survival after X-
ray exposure is illustrated in Figure 3.20. The ?̅?-value for X-ray treatment alone was 
found to be 2.92  0.12 Gy. While pre-treatment of these cells with AG-1478 or ABT-
263 yielded no measurable change in radiosensitivity, NVP-BEZ235 pre-treatment 
resulted in a significant radiosensitisation (P = 0.0125; Table 3.12). An AG-
1478/ABT-263 cocktail pre-treatment also had no effect on radiosensitivity. However, 
pre-treatment with the other inhibitor cocktails yielded an enhanced 
radiosensitisation.  
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Figure 3.20: Cell survival curves for the human lung cancer cell line (A549) after X-ray irradiation. 
Cells were irradiated without or in the presence of AG-1478 (AG), NVP-BEZ235 (BEZ), and ABT-263 
(ABT), administered either singly or in combination. Symbols represent the mean surviving fraction ± 
SEM from three independent experiments. 
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3.7. Treatment-Induced Changes in Metabolic Activity 
 
In this study, the MTT assay was used to evaluate the radiation-induced metabolic 
activity of breast, lung, and cervical cell lines at 0.5, 2, 24 and 52 hours (for early, 
intermediate, and late changes in metabolic activity) after single or inhibitor cocktail 
and 2 Gy of X-ray treatment.  
 
As described under Section 2.10, the treatment-induced modifying factors are 
summarised in Tables 3.13A-3.13B for the 0.5-hour time point. At this time point, all 
treatment configurations resulted in increased metabolic activity (MF < 1.0) in the 
breast cell lines (Table 3.13A). The data in Table 3.13B demonstrate that only the 
HeLa cell line showed decreased metabolic activity for all treatments.  
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Table 3.13A: Modifying factors (MF), relative to X-ray treatment alone (2 Gy), derived from the 
relative metabolic activities, as described in Section 2.11 for 3 human breast cell lines (normal: MCF-
12A; cancer: MCF-7, MDA-MB-231), 0.5 hours after treatment. Errors were calculated using error 
propagation formulae for ratios. 
 
 
Cell line Treatment MF 
 
MCF-12A 
2 Gy + AG-1478 0.68 ± 0.02 
2 Gy + NVP-BEZ235 0.76 ± 0.03    
2 Gy + ABT-263  0.74 ± 0.04 
 
MDA-MB-231 
2 Gy + AG-1478 0.66 ± 0.04 
2 Gy + NVP-BEZ235 0.57 ± 0.06 
2 Gy + ABT-263  0.32 ± 0.03  
 
MCF-7 
2 Gy + AG-1478 0.79 ± 0.11 
2 Gy + NVP-BEZ235 0.58 ± 0.05 
2 Gy + ABT-263  0.54 ± 0.06 
 
MCF-12A 
2 Gy + AG-1478 + NVP-BEZ235 0.77 ± 0.04 
2 Gy + NVP-BEZ235 + ABT-263 0.72 ± 0.05    
2 Gy + ABT-263 +  AG-1478 0.46 ± 0.07 
 
MDA-MB-231 
2 Gy + AG-1478 + NVP-BEZ235 0.49 ± 0.02  
2 Gy + NVP-BEZ235 + ABT-263 0.31 ± 0.01 
2 Gy + ABT-263 +  AG-1478 0.30 ± 0.02 
 
MCF-7 
2 Gy + AG-1478 + NVP-BEZ235 0.47 ± 0.05  
2 Gy + NVP-BEZ235 + ABT-263 0.51 ± 0.06 
2 Gy + ABT-263 +  AG-1478 0.58 ± 0.08 
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Table 3.13B: Modifying factors (MF), relative to X-ray treatment alone (2 Gy), derived from the 
relative metabolic activities, as described in Section 2.11 for 2 human lung cell lines (normal: L132; 
cancer: A549), and a cervical cancer cell line (HeLa), 0.5 hours after treatment. Errors were 
calculated using error propagation formulae for ratios. 
 
 
Cell line Treatment MF 
 
L132 
2 Gy + AG-1478 0.66 ± 0.02 
2 Gy + NVP-BEZ235 0.58 ± 0.09    
2 Gy + ABT-263  0.68 ± 0.06 
 
HeLa 
2 Gy + AG-1478 1.85 ± 0.15 
2 Gy + NVP-BEZ235 1.36 ± 0.17 
2 Gy + ABT-263  1.22 ± 0.14  
 
A549 
2 Gy + AG-1478 0.73 ± 0.05 
2 Gy + NVP-BEZ235 0.80 ± 0.07 
2 Gy + ABT-263  0.81 ± 0.06 
 
L132 
2 Gy + AG-1478 + NVP-BEZ235 0.85 ± 0.04 
2 Gy + NVP-BEZ235 + ABT-263 0.81 ± 0.05    
2 Gy + ABT-263 +  AG-1478 0.68 ± 0.04 
 
HeLa 
2 Gy + AG-1478 + NVP-BEZ235 1.09 ± 0.16  
2 Gy + NVP-BEZ235 + ABT-263 1.04 ± 0.12 
2 Gy + ABT-263 +  AG-1478 1.50 ± 0.17 
 
A549 
2 Gy + AG-1478 + NVP-BEZ235 0.82 ± 0.07  
2 Gy + NVP-BEZ235 + ABT-263 0.88 ± 0.09 
2 Gy + ABT-263 +  AG-1478 0.61 ± 0.05 
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At 2 hours, single inhibitor treatment of the MCF-12A cell line had no effect on 
radiation-induced metabolic activity (Table 3.14A). Treatment of the MDA-MB-231 
and MCF-7 cell lines with the inhibitors tended to decreased and increased 
metabolic activity, respectively. While combined treatment of the MCF-12A cells with 
ABT-263 and AG-1478 had no effect, concomitant treatment with NVP-BEZ235 and 
ABT-263 or AG-1478 resulted in a decrease (MF > 1.0). Combined treatment of the 
MDA-MB-231 and MCF-7 cell lines tended to decrease metabolic activity.  
 
 For the L132 cell line, single inhibitor treatment showed a decrease in metabolic 
activity (Table 3.14B). Combination treatment of these cells with NVP-BEZ235 and 
ABT-263 also resulted in a decrease, while ABT-263 and AG-1478 treatment led to 
an increase (MF < 1.0) in activity. Concomitant treatment with AG-1478 and NVP-
BEZ235 had no effect. Except for irradiation with NVP-BEZ235, which resulted in a 
reduction in metabolic activity (MF > 1.0) in the HeLa cell line, all other treatments 
showed an increase. While irradiation with AG-1478 had no effect on metabolic 
activity of A549 cells, the other inhibitors showed a decrease.  Whereas combined 
treatment with NVP-BEZ235 and ABT-263 resulted in decreased activity in these 
cells, other combinations tended to show an increase. 
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Table 3.14A: Modifying factors (MF), relative to X-ray treatment alone (2 Gy), derived from the 
relative metabolic activities, as described in Section 2.11 for 3 human breast cell lines (normal: MCF-
12A; cancer: MCF-7, MDA-MB-231), 2 hours after treatment. Errors were calculated using error 
propagation formulae for ratios. 
 
 
Cell line Treatment MF 
 
MCF-12A 
2 Gy + AG-1478 0.90 ± 0.10 
2 Gy + NVP-BEZ235 1.10 ± 0.13 
2 Gy + ABT-263  0.90 ± 0.13 
 
MDA-MB-231 
2 Gy + AG-1478 1.15 ± 0.14 
2 Gy + NVP-BEZ235 1.25 ± 0.19 
2 Gy + ABT-263  1.17 ± 0.13 
 
MCF-7 
2 Gy + AG-1478 0.84 ± 0.13 
2 Gy + NVP-BEZ235 0.88 ± 0.16 
2 Gy + ABT-263  0.90 ± 0.15 
 
MCF-12A 
2 Gy + AG-1478 + NVP-BEZ235 1.50 ± 0.26 
2 Gy + NVP-BEZ235 + ABT-263 1.71 ± 0.21 
2 Gy + ABT-263 +  AG-1478 0.96 ± 0.21 
 
MDA-MB-231 
2 Gy + AG-1478 + NVP-BEZ235 1.18 ± 0.16 
2 Gy + NVP-BEZ235 + ABT-263 1.23 ± 0.14 
2 Gy + ABT-263 +  AG-1478 1.57 ± 0.20 
 
MCF-7 
2 Gy + AG-1478 + NVP-BEZ235 1.08 ± 0.20 
2 Gy + NVP-BEZ235 + ABT-263 1.26 ± 0.20 
2 Gy + ABT-263 +  AG-1478 1.03 ± 0.21 
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Table 3.14B: Modifying factors (MF), relative to X-ray treatment alone (2 Gy), derived from the 
relative metabolic activities, as described in Section 2.11 for 2 human lung cell lines (normal: L132; 
cancer: A549), and a cervical cancer cell line (HeLa), 2 hours after treatment. Errors were calculated 
using error propagation formulae for ratios. 
 
At 24 hours, single and combined inhibitor treatment of the MCF-12A cell line shows 
decreased metabolic activity, MF >1.0 (Table 3.15A). For both treatments, the MCF-
Cell line Treatment MF 
 
L132 
2 Gy + AG-1478 1.48 ± 0.10 
2 Gy + NVP-BEZ235 1.23 ± 0.09  
2 Gy + ABT-263  1.52 ± 0.12 
 
HeLa 
2 Gy + AG-1478 0.70 ± 0.11 
2 Gy + NVP-BEZ235 1.35 ± 0.13 
2 Gy + ABT-263  0.77 ± 0.09 
 
A549 
2 Gy + AG-1478 0.94 ± 0.13 
2 Gy + NVP-BEZ235 1.30 ± 0.19 
2 Gy + ABT-263  1.17 ± 0.16 
 
L132 
2 Gy + AG-1478+ NVP-BEZ235 0.93 ± 0.13 
2 Gy + NVP-BEZ235 + ABT-263 1.62 ± 0.11 
2 Gy + ABT-263 +  AG-1478 0.80 ± 0.08 
 
HeLa 
2 Gy + AG-1478+ NVP-BEZ235 0.82 ± 0.07 
2 Gy + NVP-BEZ235 + ABT-263 0.76 ± 0.08 
2 Gy + ABT-263 +  AG-1478 0.78 ± 0.10 
 
A549 
2 Gy + AG-1478+ NVP-BEZ235 0.84 ± 0.13 
2 Gy + NVP-BEZ235 + ABT-263 1.30 ± 0.21 
2 Gy + ABT-263 +  AG-1478 0.93 ± 0.21 
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7 cell line showed increased activity. Except for single treatment with ABT-263, 
which showed increased activity in the MDA-MB-231 cell line, all other treatments 
had no effect. On average, all combination treatments resulted in decreased, no 
effect, and increased radiation-induced metabolic activity for the MCF-12A, MDA-
MB-231, and MCF-7 cell lines, respectively. 
 
In the L132 cell line, single inhibitor treatment resulted in a reduction in metabolic 
activity, except for ABT-263 which showed an increase (Table 3.15B). Combination 
treatment with AG-1478/NVP-BEZ235, NVP-BEZ235/ABT-263, and ABT-263/AG-
1478 led to decreased, no effect, and increased activity in these cells, respectively. 
Radiation-induced metabolic activity increased across the board, 2 hours after all 
treatments in the HeLa cell line. Except for treatment with AG-1478 which showed no 
effect, the other inhibitors showed a decrease in metabolic activity in the A549 cell 
line. All combination treatments, however, showed an increase in metabolic activity. 
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Table 3.15A: Modifying factors (MF), relative to X-ray treatment alone (2 Gy), derived from the 
relative metabolic activities, as described in Section 2.11 for 3 human breast cell lines (normal: MCF-
12A; cancer: MCF-7, MDA-MB-231), 24 hours after treatment. Errors were calculated using error 
propagation formulae for ratios. 
 
 
Cell line Treatment MF 
 
MCF-12A 
2 Gy + AG-1478 1.09 ± 0.09 
2 Gy + NVP-BEZ235 1.15 ± 0.20 
2 Gy + ABT-263  1.43 ± 0.10 
 
MDA-MB-231 
2 Gy + AG-1478 1.00 ± 0.10 
2 Gy + NVP-BEZ235 0.99 ± 0.21 
2 Gy + ABT-263  0.51 ± 0.10 
 
MCF-7 
2 Gy + AG-1478 0.67 ± 0.14 
2 Gy + NVP-BEZ235 0.83 ± 0.11 
2 Gy + ABT-263  0.62 ± 0.10 
 
MCF-12A 
2 Gy + AG-1478 + NVP-BEZ235 1.55 ± 0.18 
2 Gy + NVP-BEZ235 + ABT-263 1.37 ± 0.17 
2 Gy + ABT-263 +  AG-1478 1.17 ± 0.08 
 
MDA-MB-231 
2 Gy + AG-1478 + NVP-BEZ235 1.10 ± 0.18 
2 Gy + NVP-BEZ235 + ABT-263 1.01 ± 0.15 
2 Gy + ABT-263 +  AG-1478 1.13 ± 0.20 
 
MCF-7 
2 Gy + AG-1478 + NVP-BEZ235 0.69 ± 0.11 
2 Gy + NVP-BEZ235 + ABT-263 0.90 ± 0.17 
2 Gy + ABT-263 +  AG-1478 0.41 ± 0.06 
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Table 3.15B: Modifying factors (MF), relative to X-ray treatment alone (2 Gy), derived from the 
relative metabolic activities, as described in Section 2.11 for 2 human lung cell lines (normal: L132; 
cancer: A549), and a cervical cancer cell line (HeLa), 24 hours after treatment. Errors were calculated 
using error propagation formulae for ratios. 
 
At 52 hours, all treatments tended to decrease (MF > 1.0) metabolic activity in the 
MCF-12A cell line (Table 3.16A). Treatment with AG-1478 increased activity in the 
Cell line Treatment MF 
 
L132 
2 Gy + AG-1478 1.30 ± 0.12 
2 Gy + NVP-BEZ235 1.63 ± 0.21 
2 Gy + ABT-263  0.80 ± 0.10 
 
HeLa 
2 Gy + AG-1478 1.29 ± 0.07 
2 Gy + NVP-BEZ235 1.88 ± 0.34 
2 Gy + ABT-263  2.54 ± 0.27 
 
A549 
2 Gy + AG-1478 1.00 ± 0.08 
2 Gy + NVP-BEZ235 1.38 ± 0.10 
2 Gy + ABT-263  1.40 ± 0.13 
 
L132 
2 Gy + AG-1478 + NVP-BEZ235 1.59 ± 0.14 
2 Gy + NVP-BEZ235 + ABT-263 0.96 ± 0.16 
2 Gy + ABT-263 +  AG-1478 0.58 ± 0.06 
 
HeLa 
2 Gy + AG-1478 + NVP-BEZ235 2.13 ± 0.26 
2 Gy + NVP-BEZ235 + ABT-263 2.14 ± 0.14 
2 Gy + ABT-263 +  AG-1478 2.11 ± 0.16 
 
A549 
2 Gy + AG-1478 + NVP-BEZ235 0.84 ± 0.13 
2 Gy + NVP-BEZ235 + ABT-263 0.77 ± 0.09 
2 Gy + ABT-263 +  AG-1478 0.74 ± 0.22 
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MDA-MB-231 cell line, whereas the other inhibitors showed a decrease. NVP-
BEZ235 and ABT-263 combination treatment of these cells resulted in increased 
metabolic activity, while the other inhibitor combinations showed a decrease. Except 
for AG-1478 treatment in MCF-7 cells, which showed a decrease, all other 
treatments resulted in an increase in metabolic activity. 
 
On average, metabolic activity in the L132 cell line for all treatments tended to 
decrease (Table 3.16B). For the cervical cell line (HeLa), all treatments showed an 
increase in metabolic activity (MF < 1.0). In general, all treatments resulted in 
increased metabolic activity in the A549 cell line. 
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Table 3.16A: Modifying factors (MF), relative to X-ray treatment alone (2 Gy), derived from the 
relative metabolic activities, as described in Section 2.11 for 3 human breast cell lines (normal: MCF-
12A; cancer: MCF-7, MDA-MB-231), 52 hours after treatment. Errors were calculated using error 
propagation formulae for ratios. 
 
 
Cell line Treatment MF 
 
MCF-12A 
2 Gy + AG-1478 1.94 ± 0.36 
2 Gy + NVP-BEZ235 1.32 ± 0.25 
2 Gy + ABT-263  1.55 ± 0.31 
 
MDA-MB-231 
2 Gy + AG-1478 0.84 ± 0.01 
2 Gy + NVP-BEZ235 1.05 ± 0.08 
2 Gy + ABT-263  1.33 ± 0.73 
 
MCF-7 
2 Gy + AG-1478 1.24 ± 0.24 
2 Gy + NVP-BEZ235 0.59 ± 0.15 
2 Gy + ABT-263  0.88 ± 0.13 
 
MCF-12A 
2 Gy + AG-1478 + NVP-BEZ235 1.06 ± 0.23 
2 Gy + NVP-BEZ235 + ABT-263 1.33 ± 0.26 
2 Gy + ABT-263 +  AG-1478 1.04 ± 0.23 
 
MDA-MB-231 
2 Gy + AG-1478 + NVP-BEZ235 1.26 ± 0.23 
2 Gy + NVP-BEZ235 + ABT-263 0.90 ± 0.13 
2 Gy + ABT-263 +  AG-1478 2.51 ± 0.29 
 
MCF-7 
2 Gy + AG-1478 + NVP-BEZ235 0.60 ± 0.10 
2 Gy + NVP-BEZ235 + ABT-263 0.60 ± 0.08 
2 Gy + ABT-263 +  AG-1478 0.29 ± 0.05 
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Table 3.16B: Modifying factors (MF), relative to X-ray treatment alone (2 Gy), derived from the 
relative metabolic activities, as described in Section 2.11 for 2 human lung cell lines (normal: L132; 
cancer: A549), and a cervical cancer cell line (HeLa), 52 hours after treatment. Errors were calculated 
using error propagation formulae for ratios. 
 
 
 
Cell line Treatment MF 
 
L132 
2 Gy + AG-1478 1.12 ± 0.11 
2 Gy + NVP-BEZ235 1.12 ± 0.11 
2 Gy + ABT-263  1.07 ± 0.11 
 
HeLa 
2 Gy + AG-1478 0.64 ± 0.08 
2 Gy + NVP-BEZ235 0.51 ± 0.09 
2 Gy + ABT-263  0.38 ± 0.05 
 
A549 
2 Gy + AG-1478 0.95 ± 0.06 
2 Gy + NVP-BEZ235 0.96 ± 0.08 
2 Gy + ABT-263  0.86 ± 0.06 
 
L132 
2 Gy + AG-1478 + NVP-BEZ235 1.59 ± 0.24 
2 Gy + NVP-BEZ235 + ABT-263 1.01 ± 0.09 
2 Gy + ABT-263 +  AG-1478 1.61 ± 0.20 
 
HeLa 
2 Gy + AG-1478 + NVP-BEZ235 0.68 ± 0.08 
2 Gy + NVP-BEZ235 + ABT-263 0.68 ± 0.08 
2 Gy + ABT-263 +  AG-1478 0.28 ± 0.03 
 
A549 
2 Gy + AG-1478 + NVP-BEZ235 0.90 ± 0.07 
2 Gy + NVP-BEZ235 + ABT-263 0.91 ± 0.09 
2 Gy + ABT-263 +  AG-1478 0.88 ± 0.20 
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3.8. Relationship between Changes in Radiosensitivity and Metabolic Activity 
 
To determine whether there is a link between inhibitor-mediated radiosensitivity 
modulation and treatment-induced changes in metabolic activity, the modifying 
factors (MF) derived from cell survival and metabolic activity, as described in 
Sections 2.9 and 2.11, were plotted as depicted in Figure 3.21. The metabolic 
activity data for the 0.5-hour window was chosen, as it was the most consistent time 
point across inhibitors, singly and in combination.     
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Figure 3.21: A summary plot of modifying factors from clonogenic cell survival as a function of 
modifying factors from metabolic activity (measured 0.5 hours after treatment) for six human cell lines 
irradiated in the presence of specific inhibitors of EGFR, PI3K and mTOR, and Bcl-2. Quadrants 1 
and 3: increased metabolic activity; Quadrants 2 and 4: decreased metabolic activity; Quadrants 1 
and 2: radioprotection; Quadrants 2 and 4: radiosensitisation. Dashed lines represent no treatment-
induced effect. 
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The area of this scatter plot was divided into 4 quadrants by the lines representing 
MFMTT and MFsurvival equal to 1.0, where pre-treatment with inhibitors have no effect. 
When the data points of the breast cancer cell lines (MDA-MB-231 and  MCF-7) 
which tended to cluster at the lower edge of Quadrant 3 (minimal radiosensitisation 
with increased metabolic activity; blue ring), a high level of radiosensitisation 
appeared to be linked to enhanced metabolic activity (MFMTT < 1.0). On the other 
hand, a reduction in metabolic activity (MFMTT < 1.0) corresponds to enhanced 
radioresistance as seen for the HeLa cell line (Quadrant 2). Quadrants 1 and 4 are 
mostly devoid of data points, suggesting a potential link between metabolic changes 
and radiosensitisation may be represented by the solid green curve (Figure 3.21).    
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CHAPTER 4 
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4. DISCUSSION 
 
Radiotherapy is a standard form of cancer patient care, as it provides tumour control 
and is a complementary therapeutic option for surgery and chemotherapy. Despite 
these essential roles and the enhancement in the efficiency of radiotherapy over the 
past decades, tumour radioresistance and normal tissue toxicity remain clinical 
obstacles. The development of novel treatment protocols, which maximise the effect 
of radiation by reducing tumour radioresistance and limiting adverse normal tissue 
effects, are thus warranted.  
 
This study investigated the effect that inhibiting survival proteins (EGFR, 
PI3K/mTOR, Bcl-2) would have on the radiosensitivity of cancer cell lines (MDA-MB-
231, MCF-7, HeLa, A549) and apparently normal cell lines (MCF-12A and L132) 
(non-cancerous cells derived from human breast and lung  tissue that have been 
transformed for cell culture research). The development of novel treatment strategies 
that may broaden the therapeutic window of radiotherapy for cancers of the breast, 
lung and cervix was also assessed. The effect of concurrent inhibitor and radiation 
therapy on the metabolic activity of these cells was also evaluated, to determine 
whether a correlation exists between cellular radiosensitivity and metabolic activity. 
The outcomes of this study were derived from evaluating experimental protocols, 
described in Sections 2.1-2.12, in cell lines derived from humans. This may warrant 
further investigation in a clinical setting to determine the effect of a combined 
inhibitor and X-ray treatment modalities would have on cancer patients.              
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4.1. Intrinsic Radiosensitivity 
 
The intrinsic radiosensitivity of the triple negative breast cancer cell line (MDA-MB-
231), the subluminal A subtype of breast cancer cell line (MCF-7), the apparently 
normal breast cell line (MCF-12A), the cervical cancer cell line (HeLa), the lung 
carcinoma cell line (A549), and the apparently normal lung cell line (L132), was 
determined, using the colony forming assay (Figures 3.1 and 3.2). The overall rank 
order of increasing radiosensitivity was found to be L132  A549  MCF-12A  
HeLa  MDA-MB-231  MCF-7. Based on the surviving fraction at 2 Gy, the lung 
cancer cell line emerged as ~1.6 to 3-fold more radioresistant than the other cancer 
cell lines, with breast cancer cell lines being the most radiosensitive. A similar trend 
in radiosensitivity of the breast cell lines was also previously demonstrated 
(Hamunyela et al., 2015). The finding that the normal lung cell line (L132) is relatively 
more radioresistant than its malignant counterpart (A549) suggests that radiotherapy 
of lung cancers with features similar to those of A549 cells might have therapeutic 
benefit. It is also conceivable that a larger benefit can be derived from radiotherapy 
of breast cancers akin to the cell lines used here, considering the lung as a critical 
organ of interest. 
 
Radiation targets cellular DNA and may induce lesions which lead to programmed 
cell death (apoptosis), if these DNA lesions are not efficiently repaired (Roos et al., 
2016). In the presence of DNA damage, the activation of the p53 gene occurs to 
promote DNA repair, cell cycle arrest, and apoptosis (Shen et al., 2014). The MCF-7 
and MCF-12A cell lines express wild-type p53 (Berglind et al., 2008; Synnott et al., 
2017). However, the p53 gene has been reported to be mutated in the MDA-MB-231 
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cell line (Berglind et al., 2008). Despite the critical role that the p53 gene may play in 
the response of these cell lines to DNA damage, the current trend in radiosensitivity 
of these breast cell lines cannot be attributed to its status. However, it was 
suggested that the disparity in radiosensitivity of this panel of breast cell lines may 
be due to differences in PI3K expression (Hamunyela et al., 2015). While the 
relatively more radioresistant MDA-MB-231 and MCF-12A cell lines express wild-
type PI3K, PI3K is mutated in the MCF-7 cell line (Vasudevan et al., 2009; Carlson et 
al., 2010). The mutation of PI3K in MCF-7 may reduce PI3K/mTOR signalling and 
affect their ability of these cells to recover from radiation-induced damage 
(Hamunyela et al., 2015).  
 
The HeLa cell line has been reported to have a wild-type p53 gene that has been 
degraded by the E6 protein of the human papilloma virus (HPV) (Kralj et al., 2003, 
Marinez-Zapien et al., 2016, Fischer et al., 2017). The destruction of the p53 gene 
could inhibit the ability of the infected cervical cell line to initiate DNA repair or 
apoptotic pathways as a response to genotoxic agents like ionising radiation. These 
DNA repair aberrant cells may continue to proliferate, even after exposure to X-ray 
irradiation, and emerging relatively more radioresistant.     
 
The A549 and L132 cell lines have been reported to be p53 wild-type (Takeyama et 
al., 2004; Berglind et al., 2008). This may explain the relatively higher 
radioresistance observed in these cell lines. The SF2 found in this study for the A549 
is similar to that reported by Wouters and colleagues when the cells were irradiated 
with Linear Accelerator (LINAC) generated X-rays (Wouters et al., 2010). Also, the 
mean inactivation doses for the L132 and A549 cell lines obtained in this study are 
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comparable to those obtained Verheye-Dua and Böhm in this laboratory over two 
decades ago when the cells were irradiated with 60Co γ-rays (Verheye-Dua and 
Böhm, 1998). This indicates that when L132 and A549 is exposed to 60Co γ-rays or 
X-rays the relative biological effectiveness would be approximately 1.0, suggesting 
that similar dose of each form radiation would be required to achieve the same 
biological effect.   
   
4.2. Therapeutic Potential of X-rays 
 
The clonogenic data, presented in Figures 3.1 - 3.2 and summarised in Table 3.1, 
was also used to evaluate the relative sensitivity of each cancer cell line to X-rays. 
For this, the D50 values of the cancer cell lines were compared to those of the normal 
cells lines, to determine whether potential therapeutic benefit may be derived in a 
radiotherapy setting for cancers with features similar those of the panel of cells used 
here. 
 
These data demonstrated that a significant potential for therapeutic benefit may be 
derived from treating breast tumour cell lines (MDA-MB-231, MCF-7) with X-ray 
radiation. Subik and colleagues studied the molecular classification of 17 commonly 
used breast cell lines for studies, and showed that MDA-MB-231 and MCF-7 cell 
lines expressed the epidermal growth factor receptor (EGFR) at lower levels, while 
the apparently normal cell line (MCF-12A) had an approximately 2-fold higher 
expression (Subik et al., 2010). However, this may not be a sufficient rationale for 
the almost 3-fold relative sensitivity to X-rays seen in the MCF-7 cell line. A study by 
Toulany and colleagues has provided evidence that EGFR may activate PI3K to 
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stimulate the survival and proliferation pathways, particularly after exposure to 
radiation (Toulany et al., 2007). The mutation in the PI3K gene in the MCF-7 cell line, 
as previously mentioned may prevent this activating signal from being carried down 
the pathway to affect the ability of cells to repair DNA damage, proliferate, and 
survive. This could provide an opportunity for the wild-type p53 gene to initiate the 
apoptotic pathway, and lead to the relatively high radiosensitivity in the MCF-7 cell 
line.  
 
Studies have reported that HPV-positive cell lines are more radiosensitive than their 
HPV-negative counterparts (Vozenin et al., 2010; Pang et al., 2011; Datta et al., 
2015). Thus, a molecular component may be uniquely regulating the radiosensitivity 
of the HeLa cell line. These cells express a non-mutated EGFR at attenuated levels 
(Lida et al., 2011; Zhang et al., 2015). The difference in radiosensitivity of HeLa and 
MCF-12A may, thus, be attributed to their respective levels of EGFR expression. 
This may provide a rationale for the observed relative sensitivity and potential 
therapeutic advantage of treating HeLa cells with X-ray irradiation.   
 
No statistically significant therapeutic advantage was demonstrated when the lung 
carcinoma cell line (A549) relative to the apparently normal cell line (L132). This may 
be attributed to the fact that these cell lines are p53 wild-type and may be 
responding to X-ray irradiation similarly. Also, the absence of a significant difference 
in the radiosensitivity of these cell lines cannot be justified by EGFR expression. 
While the A549 cell line is known to express high surface levels of EGFR (Jaramillo 
et al., 2006), the L132 cell line expresses lower levels of this essential survival 
protein (Sundarraj et al., 2014). EGFR is the activating component for a variety of 
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signalling pathways, including the MAPK-Erk, PI3K-Akt and STAT pathways (Cortas 
et al., 2007; Ai et al., 2017). The signal transducers and activators of transcription 
(STAT) pathway consists of a family of proteins, which play a crucial role in cell 
proliferation and apoptosis (Haricharan and Li, 2014). A study by Yoon and 
colleagues reported that A549 cells express a higher level of STAT4, while L132 
cells expresses similar or slightly higher levels of other STAT proteins (Yoon et al., 
2019). This may provide DNA repair and growth advantages for the L132 cell line, 
and explain the slightly higher sensitivity of the A549 cell line. These cell lines have 
been shown to be generally DNA repair proficient (Roos et al., 2000; Dittmann et al., 
2005; Shin et al., 2009; Kim et al., 2012), a possible feature supporting their higher 
radioresistance in comparison with the breast and cervical cell lines.    
 
4.3. Inhibitor Cytotoxicity 
 
Clonogenic survival demonstrated that, for MDA-MB-231, MCF-7, MCF-12A, HeLa, 
A549 and L132, the NVP-BEZ235 treatment had the most potency (highest cell kill) 
(molar per molar), followed by ABT-263, and AG-1478 being the least potent. This 
trend seems to indicate that the survival of the cancer and apparently normal cell 
lines, used in this study, largely depends on the signalling of PI3K and mTOR. It can 
also be deduced from this trend that targeting multiple proteins may be more 
effective in managing cancer.  
 
Of the breast cell lines, the MCF-7 cell line required the lowest concentration of the 
PI3K/mTOR inhibitor (NVP-BEZ235) for 50% of its cell population to die. This NVP-
BEZ235-induced cell death may be attributed to an ER-mediation of PI3K activity 
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(Pozo-Guisado et al., 2002), as the MCF-12A and MDA-MB-231 cell lines are ER-
negative (Subik et al., 2010) and may not be susceptible to ER-mediation. MDA-MB-
231 required the highest concentration of the Bcl-2 inhibitor (ABT-263) for these 
levels of cell death, indicating that a p53 mutation may confer Bcl-2 inhibitor 
resistance as the MCF-7 and MCF-12A cell lines possess wild-type p53 (Berglind et 
al., 2008; Synnott et al., 2017). A greater resistance to EGFR inhibition was 
observed in the MCF-12A cell line. This was expected, as these cells are reported to 
have a higher expression of EGFR by Subik and colleagues (Subik et al., 2010). 
Of all the cell lines used in this study, the HeLa cell line required the lowest 
concentration of NVP-BEZ235 for a 50% cell killing, indicating that the PI3K/mTOR 
may play a major role in its cell survival. This could also indicate that inhibiting more 
than one protein of the same pathway may have a greater effect on cell inactivation 
than when a single survival protein is inhibited. The low expression of EGFR by 
HeLa cells, as reported by Lida and colleagues (Lida et al., 2011), could have 
resulted in these cells requiring a lower concentration of the EGFR inhibitor (AG-
1478) than the other cell lines in this study. Maldonado and colleagues reported that 
the low Bcl-2 expression observed in HeLa cells may not be solely due to the 
corrupted p53 gene (Maldonado et al., 1997). This low Bcl-2 expression may have 
impacted the concentration of ABT-263 needed to achieve a 50% killing, as the 
number of binding sites for the inhibitor would be expected to be low. 
   
Despite the observation that the A549 cell line has a high surface expression of 
EGFR and exhibits low to intermediate sensitivity to EGFR inhibition (Jaramillo et al., 
2006; 2008), these cells required less AG-1478 than the apparently normal lung cell 
line (L132) to reach 50% toxicity. The L132 cell line has a lower expression of EGFR, 
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and yet required a higher concentration of AG-1478 to reach 50% cell killing. This 
indicates that these cells are resistant to AG-1478 inhibition. This may be linked to 
resistance to PI3K/mTOR inhibition seen in the L132 cells, as EGFR is an activating 
protein for the PI3K/mTOR pathway (Maira et al., 2008). It is also likely that NVP-
BEZ235 may have been required in lower concentrations than AG-1478 and ABT 
263 in the A549 and L132 cell lines, as it is a dual inhibitor. A relatively lower to 
undetectable expression of Bcl-2 has been suggested for the A549 cell line which 
has been reported to be resistant to ABT-263 (Han et al., 2015). In this study, the 
higher EC50-value of ABT-263 for the A549 cell line (Table 3.5) indicates that these 
cells are more resistant to Bcl-2 inhibition than the L132 cells. A study by Pezzella 
and colleagues reported detectable Bcl-2 expression levels in tumour samples from 
cancer patients and basal cells of normal lung tissue (Pezzella et al., 1993). This 
may provide a rationale for the observed difference in ABT-263 sensitivity between 
A549 and L132. 
      
4.4. Therapeutic potential of AG-1478, NVP-BEZ235 and ABT-263 
 
The cytotoxic effects of AG-1478, NVP-BEZ235 and ABT-263 are concentration 
dependent (Figure 3.4 - 3.8). The corresponding EC50-values for MDA-MB-231 for 
each inhibitor produced relative sensitivities ranging from 0.24 - 1.04 (Table 3.6), 
suggesting that no potential therapeutic benefit may be derived from treating MDA-
MB-231 cells with EC50 concentrations of AG-1478, NVP-BEZ235 or ABT-263, as 
these levels of inhibitors might adversely affect the apparently normal cells (MCF-
12A), were there to represent normal tissue.  A ~2-fold enhancement in the relative 
sensitivity was observed in the MCF-7 cell line, when cells were treated with the 
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EGFR inhibitor (AG-1478). This was expected, as the apparently normal cell line 
(MCF-12A) is shown to have a 2-fold higher expression of EGFR than the MCF-7 
cells (Subik et al., 2010). A higher expression of the target protein would require a 
higher concentration of the corresponding inhibitor to inactivate it to a given extent. 
Inhibition of EGFR in breast cancers with characteristics similar to those of the MCF-
7 cell line may yield a therapeutic benefit. 
 
On average, the HeLa cells were 7- and 52-fold more sensitive to AG-1478 and 
NVP-BEZ235 treatment, compared to MCF-12A cells, indicating a potential 
therapeutic benefit for EGFR and PI3K/mTOR inhibition in cervical cancer.  This may 
be attributed to the expression of EGFR in the MCF-12A and HeLa cell lines being 
high and low, respectively.  
 
The approximately 7-fold higher sensitivity of the A549 cell line to NVP-BEZ235 
treatment than the apparently normal cells (L132), also indicates a potential 
therapeutic benefit in inhibiting PI3K and mTOR in lung cancer. The high sensitivity 
of the A549 cells to PI3K and mTOR inhibition may be due to the higher expression 
of EGFR, which might lead to an increase in PI3K/mTOR signalling in the cells, 
making them vulnerable to NVP-BEZ235.  
 
4.5. Inhibitor Interaction 
  
The combination indices (Cl) for the AG-1478/NVP-BEZ235, AG-1478/ABT-263 and 
ABT-263/NVP-BEZ235 cocktails for all breast cell lines ranged between 0.0237 and 
0.4683 (Table 3.8), indicating that the inhibitor-inhibitor interaction varied from very 
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strong synergism to synergism for each inhibitor combination (Chou, 2006). The rank 
order of increasing synergism for all three cocktails in the breast cell lines emerged 
to be MCF-12A  MCF-7  MDA-MB-231. Specifically, the findings for the ABT-
263/NVP-BEZ235 cocktail are consistent with those reported by Hamunyela and 
colleagues (Hamunyela et al., 2017).  
 
The combination indices for the same inhibitor cocktails for the HeLa cell line ranged 
from 0.0100 to 4.0835 (Table 3.10), indicating a very strong synergism in all cases, 
except for the cervical cell line (HeLa) in which cocktails containing NVP-BEZ235 
showed strong antagonism. The reason for this antagonism is not clear, but a multi-
target inhibition in cervical cancer might not yield desirable results. The very strong 
synergistic interaction between inhibitors of all cocktails in the A549 and L132 cell 
lines (Table 3.10), seems to suggest that although multiple inhibition of EGFR, 
PI3K/mTOR, and Bcl-2 in in lung cancer might be beneficial, the potential for 
inducing a significant level of normal tissue toxicity exists.  
 
4.6. Radiomodulation by Inhibitors 
  
In this study, pre-treating MCF-12A cells with NVP-BEZ235 or ABT-263 before to X-
ray irradiation significantly enhanced the radiosensitivity. These cells have been 
reported to show a high level of EGFR expression (Subik et al., 2010). As EGFR is 
the activating protein for the PI3K/Akt/mTOR pathway (Cortas et al, 2007; Ai et al., 
2017), it is conceivable that the level of intrinsic PI3K/mTOR activity would be high in 
the MCF-12A cell line. Inhibition of this increased signal before X-ray exposure could 
increase the susceptibility of the cells to undergo radiation-induced death, hence the 
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enhancement in radiosensitivty observed after NVP-BEZ235 pre-treatment. Ionising 
radiation may induce the activation of an apoptotic process, which is regulated by 
Bcl-2 family (Maier et al., 2016). Inhibiting Bcl-2 may hinder it from performing its 
regulatory function, and enhance apoptotic cell death. This may provide the rationale 
for an increase in radiosensitivity of ABT-263 pre-treated MCF-12A cells. A 
significant enhancement in radiosensitivity was also observed, when the MCF-12A 
cells were pre-treated with an inhibitor cocktail of AG-1478 and NVP-BEZ235. This 
could be a reflection of the synergistic interaction between the inhibitor components 
(Table 3.8). Similarly, a significant radiosensitisation occurred when MDA-MB-231 
cells were pre-treated with the AG-1478/NVP-BEZ235 and NVP-BEZ235/ABT-263 
cocktails. The strong synergism between the inhibitors of these cocktails may also 
have potentiated radiation-induced cell killing.  
 
The ER-positive breast carcinoma cell line (MCF-7) showed a 36% enhancement in 
radiosensitivity, when pre-treated with an NVP-BEZ235/ABT-263 cocktail, and a 19% 
enhancement when pre-treated with an ABT-263/AG-1478 cocktail. The increase in 
radiosensitivity may be attributed to the very strong synergism between the inhibitors 
that constitute these cocktails. 
 
A ~3-fold enhancement in radiosensitivity was observed when the apparently normal 
lung cell line (L132) was pre-treated with NVP-BEZ235. A similar enhancement in 
radiosensitivity was seen when these cells were pre-treated with the AG-1478/NVP-
BEZ235 and NVP-BEZ235/ABT-263 cocktails. By comparison, the lung carcinoma 
cell line (A549) only showed a 45% enhancement in radiosensitivity, when pre-
treated with NVP-BEZ235 alone and a 2-fold enhancement when pre-treated with a 
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cocktail of NVP-BEZ235 and ABT-263. The very strong synergy seen in the inhibitor 
cocktails (Table 3.10) is not correlated with a high level of radiosensitisation in these 
cells. Therefore, these treatment modalities may not be optimal for the management 
of lung cancer.  
 
A significant reduction in radiosensitivity was seen in the HeLa cell line following pre-
treated with ABT-263 alone, an NVP-BEZ235/ABT-263 cocktail, or an ABT-263/AG-
1478 cocktail. This may be due to the HPV infection of these cells, especially for the 
ABT-263. In these cells, the p53 gene is degraded by the E6 protein of the human 
papillomavirus (Kralj et al., 2003; Marinez-Zapien et al., 2016, Fischer et al., 2017). 
This degradation may render p53 incapable of initiating the pro-apoptotic pathway 
and unable to maintain the Bcl-2/Bax balance, thereby, making the cells evade 
radiation-induced p53-mediated cell death. The strong antagonism between the 
inhibitors of the cocktails might be the reason for the radioprotection of HeLa cells 
(Tables 3.10 and 3.12).  
 
4.7. Treatment-Induced Changes in Metabolic Activity 
 
The metabolic activity of the MDA-MB-231, MCF-7, MCF-12, HeLa, A549 and L-132 
cell lines was examined at various time points after treatment with inhibitors and 2 
Gy of X-rays. The 30-minute data were chosen for further evaluation as they were 
the most consistent across treatments (Table 3.13A). These data indicated that for 
the breast cell lines, all treatment strategies resulted in an enhancement (MF < 1) in 
metabolic activity. The same trend was observed for the lung cell lines (Figure 3.21). 
From these data, it appeared that a synergistic inhibitor-inhibitor interaction coincides 
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with an enhancement in metabolic activity. This notion can be supported by the 
observation that the cervical cancer cell line (HeLa), in which inhibitor antagonism 
was exhibited, showed a reduction in metabolic activity for most all treatments.  
 
 
Put together, increased metabolic activity appeared to be correlated with enhanced 
radiosensitisation, and vice versa (Figure 3.21). This finding concurs with the 
suggestion that reduced metabolic rates lead to radioresistance (Luk and 
Sutherland, 1987; Heller and Raaphorst, 1993; Moeller et al., 2005). The increase in 
metabolic activity, shortly after radiation treatment, may be due to cells attempting to 
provide energy and vital components for the DNA repair process, as cellular 
manipulation metabolism has been suggested as a hallmark of cancer (Wellen and 
Thompson, 2010; Hanahan and Weinberg, 2011; Anastasiou, 2017; Muir et al., 
2017). The increased metabolic activity in the apparently normal lung cell line (L132) 
is not unexpected, as immortalised normal cells can be expected to acquire some 
survival traits of cancer cells. From the current findings, it can be deduced that 
therapeutic strategies that lead to increased metabolic activity in cancer cells might 
be beneficial as adjuvants to radiotherapy. 
 
It may also be deduced from change in metabolic activity, 30 minutes after 
treatment, that non-proliferating cell are not necessarily non-metabolising. Although, 
a cell cycle arrest may occur after radiation-induced DNA damage (Tang et al., 
2018), tumour cells may continue to repair DNA damage, which requires vital 
metabolites provided by an active metabolism. Thus, using an MTT assay, which 
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requires cells to metabolise MTT into formazan, may provide a reliable indication of 
treatment-induced changes in cellular metabolic activity over the short term.          
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CHAPTER 5 
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5. CONCLUSION 
 
This study demonstrated that the breast cancer cell lines were relatively more 
sensitive to X-ray irradiation. While the cervical cancer cell line (HeLa) was relatively 
more sensitive to PI3K/mTOR and EGFR inhibition, the lung cancer cell line (A549) 
was more sensitive to only PI3K/mTOR and EGFR inhibition. An enhancement in 
radiosensitivity was demonstrated in the triple negative breast cancer cell line (MDA-
MB-231) when cells were pre-treated with AG-1478/NVP-BEZ235 and NVP-
BEZ235/ABT-263 cocktails. Patients presenting with cancers with characteristics 
akin to those of the MDA-MB-231 cell line may derive a therapeutic benefit when 
treated with these cocktails prior to radiotherapy. An enhancement in radiosensitivity 
was also seen in the ER-positive breast cancer cell line (MCF-7) when cells were 
pre-treated with an NVP-BEZ235/ABT-263 or ABT-263/AG-1478 cocktail. Cancers 
with characteristics similar to those of the MCF-7 cell line may be effectively 
managed with a combination of these inhibitor cocktails and radiotherapy. No 
potential therapeutic benefit could be demonstrate with any of the treatment 
strategies evaluated here for cervical cancer patients. Patients presenting with lung 
cancers, with characteristics similar to those of the A549 cell line, may experience an 
effective tumour control from the various treatment strategies, but with a potentially 
high level of normal tissue toxicity. Therapeutic strategies that enhance short-term 
metabolic activity may potentiate the efficacy of radiotherapy. 
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6. Possible Future Research Avenues 
 
 
1. It may be interesting to validate the apparent radiosensitisation of the cancer cell 
lines, using lower concentrations of target inhibitors. This may provide useful 
information on the optimum inhibitor concentrations that can be used without 
inducing normal tissue toxicity. 
 
2.  It has been reported that exposing cancer cells to fractionated radiotherapy may 
select for the cell subpopulations which contain radioresistance characteristics 
(McDermott et al., 2016). This study found that breast, lung and cervical cancer 
cell radiosensitivity may be manipulated by pre-treating these cells with EGFR, 
PI3K/mTOR, and Bcl-2 inhibitors prior to exposure to X-rays. A study exposing 
these cells to inhibitors pre-treatment and a fractionated schedule of X-rays will 
assist in elucidating the true therapeutic potential of these inhibitors. 
 
3. This study investigated the radiomodulatory effects of pre-treating breast, lung 
and cervical cancer cells with EGFR, PI3K/mTOR, BcL-2 inhibitors, 30 minutes 
prior to X-ray irradiation. It may be interesting to evaluate the radiomodulatory 
effects of administering these inhibitors at much earlier time points. Inhibition of 
targets at time points within the DNA repair window could also provide information 
on the potential role of the pathways of interest in the repair of radiation-induced 
damage. 
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4. Novel treatment strategies may be developed by evaluating the radiomodulatory 
effects of inhibiting alternative survival proteins such as, Poly(ADP-ribose) 
polymerase (PARP-1) (Dungey et al., 2009), heat shock protein 90 (Hsp90) 
(Dungey et al., 2009; Kabakov et al., 2010), insulin growth factor 1 receptor (IGF-
1R) (Chitnis et al., 2014). These pathways could also be evaluated in the cellular 
systems used in this study. 
  
5. This study evaluated the modulatory effects of a combination of EGFR, 
PI3K/mTOR, and BCl-2 inhibitors and 2-Gy dose of X-rays on the metabolic 
activity of cancer and normal cell lines. A study investigating the effect of inhibitor 
pre-treatment and doses ranging from 4-10 Gy cellular metabolic activity may 
provide insight into the metabolic changes that may occur at higher doses of X-ray 
irradiation. 
 
6. Cytotoxic validation may be derived by using molecular protocols, such as 
Western blotting and flow cytometry techniques to evaluate the action of inhibitors 
and the preferred mode of death used by the cells. 
 
7. The micronucleus assay may be used to assess the role of DNA damage repair in 
the radiomodulatory effects determined in this study.          
 
8. A study by Patruno and colleagues found an increase in PI3K and mTOR 
activation after exposing human keratinocytes to an extremely low frequency 
electromagnetic field (ELF-EMF) (Patruno et al., 2015). Evaluating the effect of an 
ELF-EMF and appropriate inhibitor treatment on cancer and normal cells may 
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provide insight into the development of a novel treatment strategies which 
enhance tumour control, but limit normal tissue toxicity. 
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